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General introduction and aims of the study 
Introduction 
1.1 Mental Retardation 
1.1.1 Definition and prevalence of mental retardation 
The American Association on Mental Retardation (AAMR) ' defines mental retardation 
(MR) as follows: Mental Retardation is a disability characterized by significant limitations 
both in intellectual functioning and in adaptive behavior as expressed in conceptual, social, 
and practical adaptive skills. This disability originates before age 18. Although not perfect, 
the intellectual criterion for the diagnosis of mental retardation is often represented by A 
Full Scale Intelligence Quotient of 70 or less (FSIÇK70) (table 1). 
Table 1: Classification of mental retardation 













Often a simplification of the FSIQ classification into two large groups is used: mild MR, 
including IQ values from 50-70 and severe MR, comprising IQ levels below 50. MR is 
estimated to affect 2-3% of the general population 2~4, counting 0.3-0.4% with severe MR 
1.1.2 Aetiology of mental retardation 
Mental retardation is the most frequent cause of serious handicap in children and young 
adults and therefore places heavy demands on the families, society and the healthcare 
system. MR can be regarded as a symptom, making the underlying causes of MR extremely 
heterogeneous and in the majority of cases unknown 4,5. 
There are several non-genetic factors, either acting prenatally or during early infancy, that 
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cause brain damage, for example: intra-uterine cytomegalovirus infection, excess maternal 
alcohol consumption during pregnancy, premature birth and perinatal hypoxia. These 
events account for 30-35% of the causes in severely and 15% in mildly retarded patients 5. 
Social, economic, cultural and other environmental factors can also influence the mental 
ability4. 
Genetic defects account for 20-25% of the severe MR and for 5-10% of the mild MR (APA, 
1994). In the Online Mendelian Inheritance in Man (OMIM), 1238 mendelian traits or 
genes involved with MR are found (December 2004). A substantial proportion of the cases 
with MR are caused by chromosomal abnormalities. These include aneuploidies (with 
trisomy 21 being the most common) and microdeietion/duplication syndromes. In recent 
years, several studies have shown that in approximate 5% of patients with unexplained MR, 
submicroscopic subtelomeric chromosomal anomalies are present6"8 
The knowledge of monogenic causes for MR is still far from being complete. Identifying 
the genes involved, especially for those cases in which MR is the only obvious symptom, is 
a difficult but challenging task. It is assumed that genes that influence cognitive function 
are ubiquitous in the human genome. To date, more such genes have been found on the X-
chromosome than on any other comparable segment of the autosomes. This might be a 
reflection of the greater ease in identifying genes on the (hemizygous) X-chromosome 
compared to the autosomes. Another, not mutually exclusive explanation lies in the 
heritability of an X-chromosomal gene defect which usually does not manifest a phenotype 
in female carriers. Therefore, X-linked defects might be considered one of the most 
frequent genetic causes of MR. 
1.2 X-linked mental retardation 
1.2.1 Classification of X-linked mental retardation 
The importance of genes on the X-chromosome in the cause of mental retardation has been 
recognised for over three decades. Two factors contributed to this recognition. Males 
outnumber females in nearly all surveys of mental retardation with an excess of about 30% 
"13. In addition, numerous families have been reported in which mental retardation 
segregated in an X-linked inheritance pattern. 
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Figure 1 : Schematic drawing of the X-chromosome. Adapted from20. 
Genes and their associated syndromes responsible for syndromic XLMR are listed on the left, whereas genes 
involved in non-syndromic XLMR are indicated on the right. Genes involved in both forms, are depicted in bold 
on the right. The OPHNI gene has been listed among the syndromic genes, in agreement with the syndromic 
phenotype present in patients with mutations in this gene (see discussion). 
Historically, X-linked mental retardation (XLMR) is divided into syndromic XLMR 
(MRXS), when the MR is associated with clinical, radiologic or metabolic features, or in 
non-syndromic (or non-specific) XLMR (MRX). Reviews in the past decades, have 
summarized the total number of XLMR entities and genes 14'22 At present, about 140 
syndromic XLMR conditions have been reported ; in almost half of these, causative 
mutations in genes have been identified, of which some were allelic. In addition, in 26 of 
the presently known 82 MRX families (reported families with lodscore >2) mutations have 
been found. Mutations have also been identified in genes implicated in both syndromic and 
non-syndromic XLMR (XNP, RSK2, FGD1, OPHNI, MECP2, SLC6A8, ARX, PQBPÌ, and 
JARID1C), which suggests that there is often no molecular basis for strictly dividing 
syndromic and non-syndromic entities 16;2I;23. 
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In figure 1 the currently known genes responsible for syndromic XLMR and non-
syndromic XLMR are indicated. 
1.2.2 Identification of XLMR genes 
Syndromic forms of XLMR are amenable to conventional positional-cloning strategies 
because families that share similar clinical phenotypes can be pooled for accurate 
localisation of the genetic defect. Owing to the lack of a distinctive phenotype and the 
extensive genetic heterogeneity, this is not possible for non-syndromic XLMR. It has been 
suggested that close to 100 genes might be involved in MRX 23'2^ To address this problem, 
large cohorts of clinically well-defined patients are required such as those being collected 
by the European XLMR consortium (www.euromrx.com) and other collaborative groups. 
Generally, there are two ways to identify candidate genes for MRX: candidate gene 
analysis (PAK3, GDI, ARX, DLG3, SLC6A8, PQBP1, FTSJ1, JARID1C) and positional 
cloning (OPHN1, ARHGEF6, TM4SF2, AGTR2, ZNF41, ZNF81, ILIRAPL1, ACSL4, 
FMR2, NLGN4). It is of note her that mutation analysis of known MRXS genes has also led 
to the identification of mutations responsible for non-syndromic phenotypes (XNP, RSK2, 
MECP2). 
The first step in a positional candidate gene approach is usually linkage analysis, followed 
by database search and mutation analysis of candidate genes selected in the linkage interval 
(chapter 2.1). 
Ropers et al., 21 analysed the linkage intervals of 125 unrelated families with MRX and 
found that the respective gene defects clustered in 3 defined regions on the X-chromosome; 
Xp22, Xpl 1 and Xq28, with 30% of all expected mutations being in Xpl 1. They searched 
in the Xpl 1 region and selected brain expressed genes to screen for mutations in families 
linked to Xpl 1. Subsequently, five genes responsible for XLMR were identified "". 
Positional cloning has been successful in the identification of 9 of the 21 known MRX 
genes. Especially translocations in mentally retarded patients provide an excellent 
opportunity to clone the X-chromosomal gene disrupted by the translocation. In chapter 2.2, 
the breakpoint cloning of an additional MRX gene is reported. Other X-chromosomal 
rearrangements, as microdeletions and inversions have also lead to the identification of 
several MRX genes. 
14 
General introduction and aims of the study 
1.2.3 Prevalence of X-linked mental retardation 
The most frequent single entity in XLMR is the fragile X (fraX) syndrome, with an 
estimated prevalence of 1 in 4000 to 6000 males 25"27. It accounts for 15-25% of all patients 
with XLMR 28. The prevalence of X-linked mental retardation has been estimated 1 in 550 
males '2, but there is a considerable variation in prevalence estimations of mental 
retardation caused by monogenic XLMR. Turner estimated that 20-25% of all male mental 
retardation is due to X-linked genetic defects 9. However, studies of various cohorts of 
persons with MR have indicated that X-linked factors could only be responsible for 8% of 
cases or less reviewed by Stevenson 29. Based on ARX mutation frequency studies, it was 
suggested that monogenic XLMR might account for not more than 10% of all male MR 'n. 
In a recent review on XLMR, a similar percentage was estimated: 12% of all male MR is 
caused by monogenic XLMR20. 
The number of identified genes mutated in syndromic or non-syndromic forms of XLMR 
has increased considerably in the past years. However, despite the strong increase of 
identified MRX genes, the number of mutations found in cohorts of sporadic male patients 
with MR, appeared to be very low 30"32. 
1.2.4 Frequency of mutations in MRX genes in male MR population 
A search for mutations of MECP2, ARX and SLC6A8 was systematically carried out in 
panels consisting of linked families and small, unlinked families 13"35. Additionally, 
mutation analysis of these genes in large cohorts of patients with an unexplained mental 
retardation has been performed (chapter 3.1 and 32·36). All three genes were found to be 
mutated in 2.1 to 6.8% of families linked to the regions of the respective gene localizations 
or small (unlinked) families compatible with X-linked inheritance (table 2). It appeared 
that the frequency of mutations in unrelated (sporadic) mentally retarded males is much 
lower, 0.13 to 0.41% (table 2). For example, based on the incidence of mutations in XLMR 
families, it was suggested that MECP2 mutations are a relatively common (l%-2%) cause 
of MR 34. However, a subsequent similar analysis of the MECP2 gene in 475 sporadic MR 
patients, suggested a much lower mutation frequency, in the range of 0.2% (chapter 3.1). 
In another study a series of 34 boys with MR and variable additional features as congenital 
encephalopathy, autism, epilepsy and stereotypic hand movements, no MECP2 mutations 
were identified 37. 
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ARX C/lSó11 6.6 2/150132 2/1501 0.13 
MECP2 2/2934 6.8 1/47531 3/694 0.43 
2/18534 
0/3437 
SLC6A8 6/29035 2.1 4/72636 4/1146 0.35 
0/420(pc) 
Indicated are the numbers of mulalions/total numbers tested Only convincing pathogenic mutations are 
concerned 
pc= personal communication, Gajja Salomons 
* = compatible with X-linked inheritance 
**= sporadic patients with MR of unknown cause (fragile X-negative and normal karyotype) 
A study of 682 mentally retarded males in whom fraX studies were normal 32, the most 
frequent mutation of the ARX gene, a polyalanine expansion from 12 to 20 alanines 
(24dup), was tested and only one pathogenic mutation was found. Several -mostly 
unpublished- studies of other groups reported similar results (reviewed by Mandel and 
Chelly 30 ). Maranduba et ai, 38 screened 4 MRX genes, (TM4SF2, ILIRAPL1, GD11, 
AGTR) in 118 mentally retarded males (25 familial and 93 isolated cases) who did not carry 
the fraX mutation. One possible pathogenic change was found in both TM4SF2 and 
IL1RAPL1. Because of this uncertainty, this study has not been included in table 2. 
Mutations in the SLC6A8 gene were searched in two different large cohorts. In the first 
male cohort (n=475), no pathogenic change was found (personal communication, G.S.) and 
in the second male cohort (n=726), four pathogenic changes and three unclassified variants 
were identified 36. 
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1.3 Genotype-phenotype studies 
The observation that mutations were found in genes both responsible for syndromic- and 
non-syndromic MR phenotypes has been referred to as the vanishing boundaries between 
MRX and MRXS forms l621 This observation has been confirmed in recent years, when 
several reports appeared on phenotype studies of patients with mutations in genes causing 
both MRX and MRXS In the next sections, the clinical information and novel unpublished 
clinical data are presented for those mutations in genes involved in several MRX and 
MRXS patients and families (OPHNl, MECP2, SLC6A8, ARX, PQBP1 and JARID1Q 
Three remaining genes known to be responsible for both XLMR forms, FGD1, XNP and 
RSK2, seem to cause rarely non-syndromic XLMR, whereas the syndromic forms, 
Aarskog-Scott, ATR-X and other XLMR-Hypotonic facies syndromes, and Coffin-Lowry 
syndrome respectively, are relatively common entities Therefore, these three 
genes/syndromes are not included in this section 
1.3.1 Oligophrenin gene (OPHNl) 
The Oligophrenin 1 gene (OPHNl) was identified in 1998 by cloning the breakpoint in a 
t(X,12) in a mentally retarded female 19 Subsequently, a frameshift mutation was identified 
in family MRX60 39 OPHNl encodes a Rho-GTPase-activating protein (rhoGAP) which 
accelerates the decay of the active GTP-bound forms of Ras homologous member A 
(RhoA), Ras-related C3 botulinum toxin substrate (Rac) and cell division cycle 42 (Cdc42) 
Thus, inactivation of OPHNl increases the activity of these small Rho GTPases, which link 
cell surface receptors to the organization of the actin cytoskeleton Other MRX genes 
known to mediate through the same pathway are ARHGEF640 and PAK.3 4' 
After the identification of OPHNl, three additional families were found with OPHNl 
mutations, table 3 and figure 2A Two families (with 4 and 5 affected males respectively) 
had a linkage interval comprising OPHNl4243, the third family included one affected male 
who showed phenotypic similarity to the other affected individuals 43 The affected patients 
from the 3 families showed a distinctive phenotype comprising moderate to severe MR, 
hypotonia, epilepsy, ataxia, strabismus and hypogenitalism In addition, brain imaging 
studies were performed in 9 affected individuals and showed widened cerebral ventricles 
17 
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(with most prominently enlarged lateral ventricles), lower cerebellar vermis agenesis or 
hypoplasia, asymmetric cerebellar hypoplasia and cystic dilatation of the cisterna magna 
with posterior dysplasia of the tentorium. 
Table 3: OPHN1 phenotype-genotype studies 
Phenotype Mutation Comments Number References 
Affected 
c.l587dell MRX60 4 
delexl9fs 5 
c.l385ins8 1 family 4 43 
Q62X sporadic 1 
Q186X 1 family 4 Unpublished 
data 
Total affected males: 18 
In some female carriers, mild mental retardation, strabismus, MRI abnormalities (diffuse 
cerebral atrophy, enlarged cisterna magna) and random X-inactivation was reported 42'43. 
Re-examination of the patient with the translocation and four affected males of MRX60, 
revealed marked strabismus, early onset complex partial seizures and moderate to severe 
MR 44. MRI analysis in the translocation patient and in two affected males from MRX60 
also revealed partial agenesis of the lobules VI and VII of the posterior vermis and slight to 
severe dilatation of lateral ventricels. Thus, mutations in the OPHNI gene cause a 
syndromic (MRXS) rather than non-syndromic phenotype (MRX). 
Recently, a screen for mutations in a cohort of syndromic and non-syndromic patients, 
revealed 5 additional families with an OPHNI mutation (Zanni el al, submitted). Clinical 
follow-up of one of these families with 4 affected males, showed ventriculomegaly in two 
affected males; one of them had a progressive and lethal hydrocephaly. 
Facial dysmorphisms .strabismus, 
hypogenitalism 
epilepsy, ventriculomegaly, 
hydrocephaly, cerebellar hypoplasia 
18 
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PH rhoGAP 
T(X;12) Q62X 0186X C.1385ins8 c.lSTSdell delexl9fs 
Figure 2A: Schematic drawing of the OPHN1 protein and the positions of the mutations associated with the 
phenotype as shown in table 3. 
The other male and one second deceased brother, had epilepsy. The fourth male was only 
mildly affected and did not have additional problems. The two living brothers showed a 
short forehead, deep set eyes and hypogonadism, additionally in one of them, a prominent 
chin, beaked nose and strabismus was seen (figure 2B), similar to the facial phenotype 
reported by Philip et al. 45. 
AU mutations identified are deletions or insertions leading to frameshifts and premature 
stops or nonsense mutations which are predicted to result in null alleles. 
Figure 2B: Two brothers with an 
OPHN1 mutation (p.Q186X). Note 
deep set eyes, short forhead in both 
and bulbous nose and prominent chin 
in left patient. 
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1.3.2 Methyl-CpG binding protein 1 gene (MECP2) 
Rett syndrome is a progressive neurological disease that primarily affects females 
(incidence 1/10,000) 4647 After reaching some early developmental milestones, affected 
children lose acquired skills such as purposeful hand use and speech usually between 6-18 
months of age Social behavior becomes impaired, many girls develop seizures and anxiety, 
and the vast majority display a continuous, stereotypic hand-wringing movement ',647. 
Mutations in the methyl-CpG-bmdmg protein 2 (MECP2) gene have been identified in up 
to 80% of female Rett syndrome cases 4ii 49. MECP2 is member of Methyl-CpG-Bmding 
protein family. It is expressed in all tissues, with high expression in brain, preferentially in 
the nuclear and postsynaptic compartments of mature neurons 5Ü MECP2 acts as a non-
global transcriptional repressor by binding to single symmetrically methylated CpGs via its 
methyl binding domain (MBD), recruiting the transcriptional corepressor Sin3A via its 
transcription repression domain (TRD), and incorporating histone deacetylases (HDAC) 1 
and 2. This leads to condensation of chromatin, which renders it inaccessible to the 
transcription machinery. The Brain-derived neurotrophic jactor (BdnJ) and the Hairy2a 
gene have been identified as specific MECP2 targets in rat brain and Xenopus, respectively 
5'"53 Bdnf is essential for neural plasticity, learning and memory, and Hairy2a has a role in 
neurogenesis 
Recently, a previously unidentified MECP2 open reading frame was found to define a new 
protein isoform (MECP2B encompassing exon 1 but not exon 2), being the predominant 
isoform in the brain and therefore relevant to Rett syndrome48. 
Most of the mutations causing Rett syndrome are predicted to cause either total or partial 
loss of function, but actually which aspect of MECP2 function is responsible for its 
phenotypic effects remains unknown. In vivo mouse studies, have demonstrated that 
MECP2 levels must be tightly regulated and that even mild overexpression of this protein 
may lead to a progressive neurological phenotype with similarity to the phenotype observed 
in a mouse model that lack normal MECP2 function 54 These findings support the 
possibility that duplications or gain-of-function mutations in MECP2 might underlie some 
cases of X-linked delayed-onset neurobehavioral disorders 
By studying expression of MECP2 in brain samples from several related 
neurodevelopmental disorders, including autism, pervasive developmental disorder, Prader-
Willi- and Angelman syndromes, significant differences in MECP2 expression from age-
20 
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classic Rett syndrome, congenital encephalopathy 
YI41X TI58M R258X V288X 
R167W 
RI 370 A140V 
cll6ldel240 Q406X I tl411del2 
P399L G428S R453Q 
non-syndromic MR, Angelman-like, Prader-Willi-like, MR +spasticity 
Figure 3: Schematic drawing of the MECP2 protein and the positions of the mutations (related to the first 
identified isoform, MECP2A) associated with the phenotypes as shown in table 4. 
matched controls were found, suggesting that multiple pathways regulate the complex 
developmental expression oiMECPl in disorders other than Rett syndrome 35. 
The spectrum of phenotypes in girls can vary from severe congenital encephalopathy, 
classic Rett syndrome, milder forms of mental retardation, referred to as the preserved 
speech variant, PSV, (chapter 3.2 and 56'57), autism 58 and even to a normal phenotype 59. 
X-chromosome inactivation (XCI) can reduce the effects of a particular mutation 59'60. 
In boys with MECP2 mutations, the clinical picture can vary considerably as well, 
depending on the nature of the mutation (table 4 and figure 3). Mutations that result in 
classical Rett syndrome in females will give rise to severe and fatal neonatal 
encephalopathy in males 6 ' · 6 2 . With the exception of a male patient with 816dup7 68, 
classical Rett syndrome has been observed in males with a MECP2 mutation combined 
with a XXY karyotype or with a mosaic MECP2 mutation, chapter 3.2 and 61"67. Angelman-
like phenotypes can be caused by mutations in MECP2, chapter 3.2 and 6 9 ·7 0 . Clinical 
evaluation of the only patient found by the screening of MECP2 mutations in a cohort of 
475 fraX negative males (chapter 3.1), showed that the index patient had gynaecomastia, 
hypotonia and truncal obesity (chapter 4.1 ). The latter two features can also be observed in 
patients with Prader-Willi syndrome (PWS). However, no MECP2 mutations could be 
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Severe MR with progressive spasticity has been reported in 3 males from one family 71. The 
obligate carrier females in his family were reported phenotypically normal, which is in 
contrast to an unrelated female patient with the same mutation who had mild-moderate MR, 
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chapter 3.2. Finally, non-syndromic MR has also been reported in males with MECP2 
mutations 3 ' ,·7 2•7 4. 
Milder phenotypes in boys generally involve the C-terminus of MECP2 and a few missense 
mutations within the MBD (reviewed by Neul and Zoghbi75). Of these, the A140V seems 
to be a recurrent mutation. Three families, with in total 15 affected males, and 2 sporadic 
male patients have been reported with this mutation so far 3 4·7 3·7 6 '7 7. The various phenotypes 
associated with the A140V mutation are, psychosis, pyramidal signs, macroorchidism-
syndrome (PPM-X syndrome)78, resting tremors and slowness of movements and manic-
depressive psychosis 7 7 and non-specific MR (MRX79)7j. Female carriers of A140V were 
normal or had mild MR. In addition, in the family of Orrico et al.,11 microcephaly, astenie 
habitus and speech difficulties were reported. Remarkably, although the missense mutation 
A140V is in the MBD and is the most frequently identified MECP2 mutation in mentally 
retarded males, it has never been reported in classical Rett syndrome in females. This might 
be explained by the observation that the protein with the A140V performs nearly identical 
to wild type MECP2 as demonstrated by in vitro studies of binding properties of MECP2 to 
methylated heterochromatic regions 79. Therefore this appears to be a mild mutation which 
in heterozygotes only leads to minor or no effects at all. 
1.3.3 Creatine transporter gene (SLC6A8) 
Mutations in the creatine transporter gene SLC6A8 lead to severe mental retardation in 
males, whereas in about half of the population of female carriers mild learning disabilities 
appeared to be common M. Complete absence of creatine and phosphocreatine in the brain, 
as revealed by brain proton magnetic-resonance spectroscopy (Η-MRS), increased 
creatinexreatinine ratios in plasma and urine, but normal guanidinoacetate levels are 
pathognomonic for this disorder, and at physiological concentrations, the uptake of creatine 
into fibroblasts from male patients is markedly impaired. So far, the clinical details of 15 
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Figure 4 Schematic drawing of the SLC6A8 protein and the positions of the mutations associated with the 
phenotypes as shown in table 5. 
The phenotype comprises mental retardation, autistic behavior, epilepsy and expressive 
speech and language delay. Additionally, there seems to be a unique cognitive profile 
present in affected boys encompassing ADHD, semantic-pragmatic language disorder and 
oral dyspraxia 9Ü. Evaluation of the clinical features of three affected males and two carrier 
females of two unrelated families with a mutation in the SLC6A8 gene, allowed the 
extension of the phenotypic spectrum (chapter 4.3). There seems to be a difference in 
clinical features among the patients at childhood age and at older age. Features commonly 
present in the adult patients are, myopathic facies (including ptosis), gastro-intestinal 
problems namely megacolon, severe constipation and bowel ileus, and mood disorders. 
Several reasons might account for this observation. It is possible that there is a selection 
bias in the identified younger patients. Almost all index patients underwent brain H-MRS 
as part of a diagnostic workup because of encephalopathy, expressive language difficulties 
and seizures, and were diagnosed based on the absence of creatine in the metabolite spectra. 
In contrast, the older patients were identified through candidate gene analysis and by 
screening of the SLC6A8 gene in a large XLMR cohort, without prior knowledge of 
phenotypic characteristics However, clinical examination was not performed 
extensively in all patients, so symptoms might be present that are yet not reported or it 
might be that the condition is progressive and gives rise to other features at later age. 
Clinical follow-up should give more insight in the phenotypic outcome later in life. 
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Table 5 SLC6A8 phenotype-genotype relations 
Phenotype 
Childhood/adolescent age 
Low weight, low height, poor 
muscle build, hypotonia, 
seizures, expressive language 
delay, movement disorder, 
behaviour problems 
Adult age 
Short stature, ptosis, myopathic 
facies, midface hypoplasia, soft 
skin, hypotonia, intestinal 
problems, spastic/dystomc gait, 
seizures, mood/behaviour 
problems 
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Total affected males: 33 
The prevalence of mutations in SLC6A8 gene was estimated to be at least 2 1% in a cohort 
of 290 unrelated families of the European-XLMR consortium (www euromrx com), as in 
total, 6 pathogenic sequence changes were found 3 5 Although this suggested that mutations 
in this gene might be more common among patients with unexplained MR than appreciated 
so far, SLC6A8 mutation analysis in a cohort of almost 1000 fragileX negative males, did 
not confirm this suggestion 3 6 (and personal communication G S) 
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1.3.4 Aristaless related homeobox gene (ARX) 
Mutations in the ARX gene, cause several different MR syndromes 92. The ARX predicted 
protein belongs to a large family of homeobox proteins and is characterized by a C-terminal 
Aristaless domain and an octapeptide domain near the N-terminus. It is thought to be 
involved in neuronal proliferation and GABAergic neuronal differentiation 93. The 
phenotypic expression varies from non-syndromic MR (figure 5A), to syndromic forms 
such as Partington syndrome, characterized by seizures, dystonia and mental retardation 94" 
97, West syndrome (ISSX, X-linked infantile spasms syndrome with hypsarrhythmia and 
mental retardation)9I;97 and mental retardation with myoclonic epilepsy and spasticity 9 2 '9 9 
(table 6 and figure 5). Van Esch et αι., "Il) reported a boy with median cleft lip and palate, 
transphenoidal encephalocele and hypopituitarism whereas his uncle had Partington 
syndrome. The most severe end of the clinical spectrum of conditions associated with ARX 
mutations is X-linked lissencephaly with absent corpus callosum and ambiguous genitalia 
(XLAG)101. 
Figure 5A: Affected males of MRX76 with dup(24bp) in ARX. Some have dysmorphic features, but there is no 
facial feature consistently present among the affected. 
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ACC' agenesis of the corpus callosum AG: abnormal genital 
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It was found that Arx knockout mice had small brains due to impaired neuronal 
proliferation '0'. Moreover, the number of gamma-aminobutyric acid (GABA)-ergic 
intemeurons was markedly reduced in the cortex and the striatum, and their migration was 
disturbed. 
In several female relatives of male patients with XLAG, isolated agenesis of the corpus 
callosum (ACC) was present l02. In the same article it was reported that mutations of ARX 
are associated with striking pieiotropy and consistent genotype-phenotype correlation. At 
the other hand, several families have been reported with marked intrafamilial variability. 
For example Turner et ai, 'ü3 described a family with four affected males who had the same 
mutation; one man had the West syndrome, another the Partington syndrome and two 
others non-syndromic MR. Moreover, a study of 46 males with the 428-451 dup(24bp) 
showed that he clinical picture is variable96. The degree of MR ranged from mild to severe, 
infantile spasms occurred in 12.5% and other less severe forms of seizures in 37.5%. 
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non-syndromic MR, Partington/West syndrome, Myocloniscepilepsy 
Figure 5B Schematic drawing of the ARX protein and the positions of the mutations associated with the 
phenolype as shown in table 6 
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Summarizing the phenotype-genotype analysis XLAG or related syndromes are caused by 
premature termination mutations consisting of large deletions, frameshifts, nonsense 
mutations and splice site mutations as well as missense mutations involving the 
evolutionär!ly conserved homeobox domain of this protein '0' '02 '(M Infantile spasm 
syndrome including Partington and West syndrome, is caused by an additional stretch of 7 
GCG repeats within the normal stretch of 10 GCG triplet repeats in exon 2 or by a 24-bp 
duplication in exon 2 duplicating nucleotides 428-451 92 This entity can also be caused by 
a large deletion including part of intron 4 and the entire exon 5 of ARX In the family 
with mental retardation, myoclonic epilepsy and spasticity, a missense mutation (p P353L) 
was identified n Finally, non-syndromic mental retardation is mostly due to the expansion 
of poly-alanine stretches in the protein as well, resulting from the insertion of two to eight 
GCG trinucleotides in the gene " 9 2 
1.3.5 Polyglutamine Binding Protein 1 gene (PQBP1) 
The Polyglutamine Binding Protein 1 (PQBP1) was identified in 1999 and is supposed to 
interact with expanded polyglutamine tracts of huntingtin, ataxin and androgen receptor ' ' ' 
113 Mutations in the gene resulting in XLMR, were first identified in 5 families "4 and 
subsequently in several additional families "5 (table 7 and figure 6) Kalscheuer et al, 1M 
found 3 different frameshift mutations in the polar-amino acid-rich domain (PRD) of the 
PQBP1 gene in 5 out of 29 XLMR families with overlapping linkage intervals, including 
patients with Sutherland-Haan syndrome "6, Hamel cerebropalatocardiac syndrome "7, and 
nonsyndromic XLMR "8 Mutations truncating the nuclear localization signal (NLS) and 
the more C-terminal C2 domain, were identified by Lenski et al, '15 in the family originally 
described by Renpennmg et al, "9 and in another Renpennmg family with MR, short 
stature and microcephaly Recently, mutations in PQBPl have been found in the family 
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Figure 6 Schematic drawing of the PQBP1 protein and the positions of the mutations associated with the 
phenotypes as shown in table 7 
It was reported that PQBP1 mutations give rise to defective pre-mRNA splicing in the 
nucleus because of a disturbed interaction of the C2 domain with proteins involved in a 
nuclear pre-mRNA splicing machinery. A possible exception is the missense mutation in 
the WW domain that has recently been detected in a family with Golabi-Ito-Hall syndrome 
l20. This mutation alters the highly conserved hydrophobic aspects of the WW domain, 
thereby possibly disturbing the interaction with RNA polymerase II. This might explain the 
ectodermal features observed during childhood in the Golabi-Ito-Hall syndrome but not in 
the other syndromes. 
A clinical study was conducted in 7 affected patients from 3 families and the clinical 
hallmarks were compared to those of the other reported families. Features seen in these 
patients are mental retardation (70% severe MR), microcephaly (93%), short stature and 
lean habitus (61%), post-adolescent facial characteristics, small testes (32%), spastic 
diplegia (20%) and midline defects (chapter 4.2). 
30 
General introduction and aims of the study 
Table 7: PQBP1 phenotype-genotype relations 























































Total affected males: 52 
1.3.6 Jumonji AT-rich interactive domain 1C (JARIDIC) 
Mutations in the gene JARID1CISMCX were recently found to cause XLMR '24. It has been 
shown that JARIDIC, which is an abbreviation for Jumonji AT-rich interactive domain 1C, 
escapes X-inactivation and that the gene has an homologous gene (JARIDID/SMCY) on the 
Y-chromosome '25. All JARID genes show strong homology to the transcription factor 
RBBP2, which is assumed to play a role in chromatin remodelling '26. 
As the gene was identified only very recently, clinical data of patients with JARIDIC 
mutations are very scarce (figure 7). Some are non-syndromic while in others, a syndromic 




















strabismus, hypermetropia, diastema of teeth, cryptorchism, (progressive) spasticity, 
epilepsy and behavioural or mood problems. A combination of these features seems 
indicative for presence of JARIDIC mutations. 
PHD Zinc finger JmjC 
JmjN Arid/Bright C5HC2 Zinc finger PHD Zinc finger 
R68fs R694X L731F WI288X 
Figure 7: Schematic drawing of the JARIDIC protein and the positions of the reported mutations. 
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1.4 Aims of the study 
Mental retardation is a cognitive disorder that affects 2%-3% of the western-European 
population In the majonty of cases the aetiology remains unexplained It is well 
established, however, that genetic defects on the X-chromosome contribute significantly to 
the incidence of mental handicaps Despite the high impact of XLMR on the families 
involved and on the society as a whole, only a minority of patients has been diagnosed with 
a molecular defect Therefore the general goal of this project was, to increase the 
possibilities for DNA diagnostics and genetic counselling in patients with so far 
unexplained MR 
For this general aim, we had three objectives 
1) To identify novel MRX genes from families to genes 
Linkage analysis is traditionally used to localize the genetic defect Unfortunately, the 
resulting linkage intervals are usually very large in case of non-syndromic MR, because 
pooling of interfamihal mapping data results is not possible Nevertheless, linkage studies 
have proven to be instrumental in MRX gene identification strategies that focus on 
candidate genes in a particular chromosomal region One example of this strategy is given 
in chapter 2 Linkage analysis in a large family with several affected males defined a locus 
on the X-chromosome Subsequent mutation analysis of positional candidate genes 
mapping to this interval, led to the identification of a causative genetic defect in this family 
Another important and rewarding approach to identify novel MRX genes is positional 
cloning The analysis of X-chromosomal breakpoints in mentally retarded patients can be 
used to identify the causative, breakpoint spanning gene within a larger interval to which 
the genetic defect was previously mapped in other families One such region on the X-
chromosome, which is common to the overlapping linkage intervals in several MRX 
families, is located in the Xpl 1 region The high number of families linked to this region, 
could either mean that it contains an unknown MRX gene that is frequently mutated, or that 
this region contains a relative high number of MRX genes Therefore we have studied the 
breakpoints of a balanced translocation t(X,9)(pll 2,q34 3) in a mentally retarded female 
(chapter 2) The X-chromosomal gene that is disrupted by the breakpoint, has been tested 
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for mutations in a representative patient panel from 24 families linked to the region and in a 
larger patient panel of 285 families from the European XLMR consortium. 
At the same time, characterization of the chromosome 9 breakpoint lead to the 
identification of a candidate gene, that underlies an autosomal MR syndrome (chapter 5). 
2) To estimate the frequency of mutations in MRX genes in several patient cohorts 
Since it appeared that some genes were mutated relatively frequently in MRX families, the 
question was raised whether routine testing of this genes would be practicable in patients 
with mental retardation of unknown cause. 
One of these genes was the MECP2 gene for which the frequency of mutations in several 
large patient cohorts was studied. Fragile X negative, Angelman negative and Prader Willi 
negative males and females were investigated by direct sequencing of the MECP2 gene to 
valuate if implementation of routine testing of this gene in a DNA diagnostics setting would 
be feasible (chapter 3). 
3) To relate the gene mutations found in MRX genes to the clinical characteristics of the 
patients: from genes to families. 
In the third part of this thesis the relation between gene mutations in MRX(S) genes and the 
clinical characteristics of the corresponding families was studied. Phenotype studies and 
genetic counseling, have been performed in patients with OPHNI, MECP2, SLC6A8, ARX, 
PQBPl and JARIDIC mutations. This allowed the detection of (minor) clinical and/or 
behavioural features that coincided with mutations in a specific MRX gene. These studies 
are valuable for future clinical diagnosis in patients with MR. Thus, besides the direct 
benefits for the family in whom the gene mutation was identified, the broader perspective 
of these studies was to increase the possibilities for DNA diagnostics and genetic 
counselling in patients with so far unexplained MR. 
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2.1 Localisation of a gene for non-specific X linked mental 
retardation (MRX76) to Xp22.3-Xp21.3 
Τ Kleefstra, HG Yntema, AR Oudakker, FA Poppelaars, BBA de Vries, MGEM Ausems, Η 
van Bokhoven, BCJ Hamel 
Am J Med Genet 2002 110 410-411 
X-linked mental retardation (XLMR) is a common condition affecting 1 8/1000 males ' 
XLMR can be classified into specific (MRXS) and nonspecific (MRX) forms In the former 
the mental retardation is part of a syndrome, in the latter the mental handicap is not 
associated with consistent phenotypic characteristics Up to now, more than 70 families 
with MRX have been reported, whereas gene defects were identified in 9 families only3 
We report on a new family with recessive non specific X linked mental retardation which 
could be assigned a causative genetic defect, MRX76 to Xp22 3-Xp21 3 
The pedigree included 8 mentally retarded males in two generations, all but one were 
clinically examined (figure 1) The latter had Down syndrome and was tested 
cytogenetically only In all patients, pregnancy and delivery were uneventful The mental 
retardation was noticed during early childhood and appeared non-progressive None of 
them had convulsions All patients were either institutionalised or living and working in a 
sheltered environment Physically they were all healthy, except for the brothers II 6 and II 8 
who were diagnosed with Wolff-Parkinson-White syndrome and Morbus Besnier Boeck 
respectively Behaviour was normal except for patient II 8 who was known with severe 
mood disorders with depressive and psychotic features He died at the age of 60 years 
The degree of mental retardation in the affected family members tested varied from 
moderate to profound The pedigree structure and clinical data are fully compatible with a 
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Figure 1 : Pedigree of two generation family with MRX. 
In order to determine the most likely location of the gene, linkage analysis with highly 
polymorphic markers distributed along the X-chromosome was performed on DNA from 27 
relatives. 
For the initial analyses, 26 markers spread along the X-chromosome were genotyped on the 
27 potentially informative family members. Once tentative linkage with DXS443 was 
obtained, other markers in the region were genotyped. The proximal marker DXS987 at 
Xp22.31 and the more distal marker DXS8039 at Xp21.3 recombined with the disease in 
the family, delimiting the probable gene location. Significant lod scores were obtained with 
markers DXS999, DXS443, DXS989, and DXS1048, with a maximum lod score of 3.79 at 
θ=0 (at DXS999 and DXS989). A reconstruction of the markers in the Xp22.31-p21.3 
region is shown in figure 1. 
Recently it was found that the RSK2 gene resposible for the Coffin-Lowry syndrome, was 
mutated in a family with non specific MR (MRX 19)4. Because the linkage interval of our 
family comprises the location of the RSK2 gene, we performed mutational analysis of this 
gene, but no mutations were found. In the recently identified gene ILIRAPL, responsible 
for the MR in MRX34 5 no mutations could be found either. 
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Many other MRX entities have been mapped to X chromosomal segments overlapping the 
linkage interval for MRX76 which has been reviewed recently by Chiurazzi et al.3 
The 9 genes identified up to now, responsible only for a minor part of the MRX families, 
are almost all involved in signalling pathways. They are expressed at the start of CNS 
differentiation and are prominently expressed in the hippocampus and in the adult brain. 
These features underscribe the importance of these genes in both pre- and postnatal 
development. The gene involved in the MRX 76 family might be a member of these 
pathways. 
Another interesting finding is that two MRXS genes, RSK2 and MECP2, are mutated in non 
specific XLMR as well. Therefore it could very well be that future studies will reveal other 
MRXS genes that play a role in MRX as well. Moreover, new genes having an effect on the 
epigenetic regulation of gene expression, might be found responsible for a substantial part 
of non specific X linked mental retardation. 
Note added in proof: 
The family described here is the same as family N52 recently described by 
Bienvenu et al.6. 
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Introduction 
Non-syndromic X-linked mental retardation (MRX) is a highly heterogeneous group of 
conditions in which mental retardation (MR) is the only consistent clinical feature in 
patients. This in contrast to syndromic forms of X-linked mental retardation (MRXS), 
where MR is associated with recognizable clinical signs such as congenital malformations, 
neurological features or metabolic disturbances. Identifying novel genes that are 
responsible for MRX is difficult, due to the heterogeneity of this disorder. At present 30 
genes have been identified as playing a role in MRXS. However, in MRX, only 15 genes 
are known to be involved accounting for less than one-fifth of all MRX ι"6. The recent 
observations that RSK2, MECP2 and /i/LVplay a role in both syndromic and non-syndromic 
forms of XLMR7,8·8"10, suggest that a molecular basis to strictly separate these two forms is 
not always present. In addition, careful clinical re-examination of patients with an OPHN1 
gene mutation has revealed distinctive phenotypic hallmarks, such as cerebellar hypoplasia, 
in patients which were previously classified as non-syndromic"12. The frequency of 
causative mutations in any of the 15 MRX genes known today appears to be very low, so in 
the majority of patients with MRX the genetic cause is still not known. It has been 
suggested that up to 100 different genes might be involved in MRX3. Seven of the fifteen 
genes have been cloned on the basis of their disruption by chromosomal rearrangements in 
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mentally retarded patients. Recently, it has been predicted that approximately 30% of all 
mutations underlying MRX are located in the Xpll.2-Xpll.3 interval 3. Only two MRX 
genes have so far been identified in this region, ZNF41 2 and PQBPI 4. In this study, we 
have characterized the breakpoint of a de novo translocation t(X;9)(pll.23;q34.3) in a 
female patient with severe mental retardation. Since the breakpoint on the X-chromosome 
is within the hotspot interval of MRX genes, it was an excellent starting point for a 
positional cloning approach to identify a novel candidate gene responsible for MRX. Fine-
mapping of the X-chromosomal breakpoint with FISH analysis and sequencing led to the 
identification of a gene, ZNF81, that was disrupted by the breakpoint. Subsequent mutation 
analysis in a cohort of MRX families revealed a missense mutation in a family that maps to 
Xpl 1.23, supporting the notion that ZNF81 is a novel MRX gene. 
Material and methods 
Propositus 
The patient is a Caucasian girl bom after 37 weeks gestation, with a birth weight of 3100 
grams (25lh centile) and a birth length of 49 cm (25'h centile). Pregnancy and delivery were 
uneventful. She is the second daughter of healthy, non-consanguineous parents. In the 
neonatal age hypotonia and feeding problems were present. The anterior fontanel was 
enlarged and closed at the age of 2 years. 
Psychomotor development was delayed, she walked at the age of 2 years and 6 months, 
with hardly any speech development. She had a mild-moderate conductive hearing loss on 
both sides. At the age of 2 years, an Atrial Septum Defect type II with a pulmonary stenosis 
was diagnosed without hemodynamic consequence. 
At the age of 4 years, she had epileptic convulsions with EEG abnormalities, but thereafter 
no more convulsions occurred and EEG patterns returned to normal. She had severe 
behavioural problems involving autistic features, aggressiveness and auto-mutilation. The 
menarche was started 10 years of age. At the age of 11 years, she was a non-cooperative, 
mildly obese girl with apparently normal height and head circumference, brachycephalic 
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skull and several facial dysmorphisms synophrys, upward slanting of the palpebral 
fissures, hypertelorism, a broad nasal bridge, protrusion of the tongue, eversion of the lower 
lip and small ears 
XL1Y1R families and controls 
DNA from approximately 300 families collected by the European XLMR Consortium, 
including 24 families with linkage to the Xpl 1 23 region (LOD score >2), were available 
for mutation screening (www euromrx com) 
DNA from 241 Caucasian control males and 105 control females was available to verify the 
incidence of nucleotide changes In addition, 217 MR males negative for FMR1 
trinucleotide expansions were also analysed for mutations in the ZNF81 gene 
Fluorescence in situ hybridization (FISH) 
BACs on chromosome Xpl 1 2 and 9q34 3 were selected from the UCSC Genome browser 
(http //genome ucsc edu) and obtained from the Max Planck Institute Berlin DNA from 
BACs was labelled with digoxigemn-dUTP by nick translation (Invitrogen) or by random 
priming with biotine-dNTP by Klenow polymerase (Roche) The hybridisation signals were 
made visible by antibody-FlTC or by avidine-Cy3 labelled antibodies on a Leica DM RA 
fluorescence microscope 
Southern blotting 
DNA samples of cell lines of the patient, one control female, X-chromosome hamster 
somatic hybrid and hamster, were digested with 5 different restriction endonucleases 
(BamHl, BglU, EcoRl, HindlU, Smal), electrophoresed on (0 6%) agarose gels and 
transferred m 1 5 M NaCl/0 5N NaOH to nylon membranes Genesereen according to 
standard protocols 
cDNA fragments or genomic DNA templates were used to generate probes by extension of 
random hexamer primers with Klenow polymerase in the presence of [j2P]dCTP Probes 
were hybridized to the Southern blots in 0 125 M P04, 0 25 M NaCl, ImM EDTA, 7% 
(w/v) SDS, 10% (w/v) PEG 6000 overnight at 650C 




A vectorette-PCR cloning procedure was used essentially as described by the manufacturer 
at www.genosys.com. Briefly, Bam\\\ digested DNA from the patient and a control was 
ligated to a phosphorylated Bam\\\-vectorette Top Strand Primer (VTSP-flamHI; 5'-
GATCCAAGGAGAGGACGCTGGTCTGTCGAAGGTAAGGAACGAACGAGAGAAG 
GGAGAG-3') and a phosphorylated Vectorette Bottom Strand Primer (VBSP; 
S'CTCTCCCTTCTCGAATCGTAACCGTTCGTACGAGAATCGCTGTCCCTCTCCTTG 
-3') o/n at 160C. The resulting vectorette libraries were amplified using a Universal Primer 
(UVP; 5'-CGAATCGTAACCGTTCGTACGAGAATCGCT-3') and gene-specific primers 
(reverse) in exon 6 (5'-CGTGGTGACTATAAGAAGAGTTC-3'and 5'-
GGGAAGGCTTAATTCCAAATTTCC-3'). The latter was used in a semi-nested PCR 
reaction. Primer positions are indicated in figure 3A. The PCR conditions were as follows: 
five cycles of 30 s at 940C, 3 min at 70 0C; five cycles of 30 s at 94 0C, 3 min at 68 0C; 25 
cycles of 30 s at 94 0C, 1 min at 66 0C, 2 min at 70 0C. PCR products were purified from 
agarose gel using Qiaquick gel extraction kit (Qiagen) and subsequently sequenced on an 
Applied Biosystems 3730 automated sequencer. 
RNA isolation and expression studies 
RNA was isolated from patient and control lymphoblastoid cells using an RNeasy kit 
(Qiagen) according to the instructions of the manufacturer. cDNA was synthesized from 
250 ng total mRNA using random hexanucleotide primers and M-MLV reverse 
transcriptase (RT; Invitrogen). RT-PCR was performed to amplify ZViW-derived 
transcripts in cells from the patient and control. For this, specific primers were selected for 
exons 1, 3 and 6 of ZNF81. A 3' RACE experiment on the patients RNA was carried out 
according to the manufacturers protocol (Invitrogen). Primer sequences are available upon 
request. 
Mutation screening in XLMR probands 
The entire coding region of the ZNF81 gene was sequenced in 536 MR patients, that is 319 
from the European XLMR Consortium and 217 MR males negative for FMR1 mutations, 
using genomic DNA as a template. Primers were designed to amplify the noncoding exons 
1 and 2 and coding exons 3-6 of the gene. Exon 6 was amplified in 3 overlapping fragments 
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(6a,b,c) Primers and PCR conditions are shown in table 1. The PCR samples were directly 
sequenced, after purification with a Qiagen PCR purification kit, on an Applied Biosystems 
3730 automated sequencer using the same primers as in the PCR. 






































Mapping of chromosome Xp 11.23 and chromosome 9q34.3 breakpoints using FISH 
Successive fluorescent in situ hybridisation with 9 overlapping BAC clones showed that 
RP11-1145B22 gave signals on the derivative chromosome X as well as on the derivative 
chromosome 9 (figure 1), which indicated that the breakpoint region on the X-chromosome 
was located within this clone The overlapping neighbouring clones, RP3-393P12 at the 
distal side and RP11-1154B20 at the proximal side, gave signals on only one of the 
translocation chromosomes, the derivative-9 and derivative-X, respectively (data not 
shown). It thus seemed, that the X-chromosomal breakpoint is located in a 40 kb fragment 
that is unique to RP11-1145B22. 
In silico analysis 
In sihco analysis using the UCSC genome browser, www.genome.ucsc.edu-goldenPath-hg 
(accessed in November 2003), revealed several spliced ESTs but no known genes, mapping 
to the breakpoint region. The spliced ESTs did not have a long open reading frame (ORF) 
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Figure 1: Patient metaphase chromosomes were used for fluorescence in situ hybridisation of X-chromosomal 
breakpoint spanning BAC clone RPl 1-1145B22 on the normal X, and a split signal was obtained on the der(X) 
and der (9) as indicated. 
However, several of these ESTs showed homology to KRAB-domain coding sequences, 
which are commonly found in Zinc Finger proteins. Further Blast searches with sequences 
from BAC RP11-1145B22 resulted in the identification of sequences encoding Zinc Finger 
motifs that had the same orientation as the KRAB-domain sequences. It appeared that 
merging of 6 of the predicted exons of the region had the capacity to form a transcript with 
an ORF of 1986 bp (661 amino acids). Part of this predicted transcript has been deposited 
previously in the Genbank. database as the Zinc Finger gene ZNF81 (Accession number 
P51508). The full length transcript has been deposited in the Genbank database with 
accession number AY487248. 
Full-length ZNF81 transcript is absent in the patient cell line 
RT-PCR was performed on RNA from cell lines of the patient, a control and hamster 
somatic cell hybrids that contained either an active (Xa) or an inactive (Xi) human X 
chromosome. 
Products of the expected sizes were obtained by RT-PCR amplification from exons 1-3 and 
from exons 1-5 in the control and in the Xa hybrid. No RT-PCR product could be amplified 
from the Xi cell line, indicating that the ZNF81 gene is subject to X-inactivation. Sequence 
analysis confirmed the proper identity of the RT-PCR products. Surprisingly, identical 
products were obtained from the patient's cell line, suggesting that the 5' end of the ZNF81 
gene is transcribed from the der(9) chromosome. RT-PCR amplification from exons 5-6, 
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was unsuccessful in the patient and in the Xi, whereas a normal product was obtained from 
the Xa and control cell lines. This result suggested that the translocation breakpoint was 
located between exons 5 and 6 (figure 2). 
To elucidate the nature of the der(9)-derived ZNF8I transcript, a 3' RACE experiment was 
performed. A single 3' RACE product was obtained, which appeared to be derived from a 
chimaeric transcript consisting of the 5' end of ZNF81 fused to a poly(A)-containing Alu 
repeat element on chromosome 9. The Alu repeat is fused to the last nucleotide of exon 5 of 
ZNF81, which indicates that the X-chromosomal breakpoint is likely located in intron 5 of 
the gene (figure 3 C). 
Π3 — nj ο — 
Χ X Q. Ο = 
Εχ1-5 
Εχ5-6 
Figure 2: RT-PCR for ZNF8Ì in somatic hybrid cell lines 
with active X-chromosome (Xa) and with inactive X-
chromosome (Xi) and in patient and control cell lines. 
Transcripts in the patient were obtained from exons 1-5, but 
not from 5-6. The (+) and (-) indicate the use of reverse 
transcriptase. 
Identification of the X chromosome breakpoint by Southern hybridisation 
Southern blot analysis was performed to narrow-down the position of the X-chromosomal 
breakpoint. An aberrant restriction fragment of 6.5 kb was observed in the patient BamW\ 
digest with the probe corresponding to the cDN A sequence of exon 5-6 of ZNF81 (figure 3 
B). The ßg/11 digest of the patient showed a 6.7 kb band of increased intensity as compared 
to the control, probably caused by the hybridisation of an aberrant restriction fragment of 
the breakpoint chromosome in combination with a normal restriction fragment of the 
wildtype allele of the same size. 
Another hybridisation with a probe containing part of exon 6, confirmed that the aberrant 
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patient t(X;9): chimeric transcript MRX45: p.S179N 
Figure 3: A, Schematic diagram (not to scale) indicating the exon-intron structures of ZNFS1 and Eu-HMTosel 
relative to the breakpoint region. Also shown is the der(9) chromosome from which the chimeric ZNF81-Alu 
transcript is generated. The der(X) chromosome, which was used as a template for the vcctorette PCR, is not 
shown. Β = BcimWX restriction site. The vectorette PCR was designed with a reverse primer in exon 6 of ZNFSI 
and a BamVW universal linker primer. The positions of both primers resulting in the vectorette PCR product arc 
indicated with an arrow head. 
B, Southern blot of genomic DNA of the patient, control and X-only somatic cell hybrid digested with BamH\. 
The probe used, corresponds to the cDNA sequence of exon 5-6 of ZNF81. The aberrant fragment specific to 
patient DNA (arrow head) corresponds to the size of approximately 6.5 kb. 
C, Schematic diagram of the chimeric product in the translocation patient and the position of the p.S179N in 
MRX45. In the chimeric transcript, the 3' end of exon 5 of ZNF81 is fused to an Alu repeat is located in intron 4 
of Eu-HMTasel in the reverse orientation. The sequence change in MRX45 is in the 5' end of exon 6 ofZNFSl. 
6.5 kb band observed in the first hybridisation in the BamH\ digest of patient DNA was 
derived from the normal 15.7 kb band (data not shown). These findings resulted in a 
reduction of the genomic breakpoint region on the X chromosome to a 816 bp region in 
intron 5 oiZNFSl. 
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Vectorette PCR 
A vectorette PCR was performed in order to determine the exact sequences at the 
chromosomal breakpoints To this end, genomic DNA from the patient was digested with 
BarnHX and ligated with a vectorette linker. A PCR reaction was then performed using a 
universal vectorette primer and a primer specific for exon 6 of the ZNFH1 gene. The 
product obtained by the vectorette PCR revealed that the breakpoint on genomic level was 
in intron 5 of ZNF81 and in intron 8 of the gene EU-HMTasel on chromosome 9 (figure 
3A) Additional PCR with primers flanking the breakpoints, exactly located the breakpoint 
to 817 bp from the S'end of exon 6 of ZNF81 and 11 bp from the 3'end of exon 8 of Eu-
HMTasel on chromosome 9 An intronic deletion of 3 bp was present, that could not be 
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Segregjlion of 
mutation ρ S179N in 
family MRX 45 
Sequence analysis 
Because Eu-HMTasel is still expressed in lymphoblasts from the patient, and complete 
ZNF81 transcripts could not be detected in the cells from the translocation patient, ZNF81 
was considered a strong candidate gene for XLMR. Therefore, representative affected 
males from 24 MRX families mapping to Xpll.2 were screened for mutations in the 
ZNF81 gene (table 2) In one of these families, family MRX45, we identified a nucleotide 
change c.536G>A in exon 6, which predicts an amino acid substitution pS179N This 
nucleotide change fully segregated with the phenotype in the family (figure 4) and was not 
identified in 451 control X-chromosomes. One more nucleotide change, c.554C>T 
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(p.S185L), was detected in another linked MRX family, but this change was also found in 
healthy control males. 
The mutation analysis was extended to another 285 affected males from unrelated XLMR 
families and 217 MR males who had been tested negative for an FMR1 mutation. In total 
one intronic and four exonic sequence alterations were found that were not known as SNPs 
in genomic databases. However, all of these 5 changes were also identified in a cohort of 
190 control male X chromosomes and 164 female X chromosomes and were therefore 
considered polymorphisms. 




































































Not present in affected brother in one family 
Not Applicable 
Discussion 
We have characterized the chromosomal breakpoints of a mentally retarded female patient 
with a de novo X;autosome translocation t(X;9)(pll.23;q34.3). The chromosomal 
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breakpoint on the X-chromosome of a mentally retarded female patient with a de novo 
X;autosome translocation t(X;9)(pl 1.23;q34.3) disrupted the coding region of a Krueppel-
type zinc finger gene ZNF81. In the patient only expression of the 5'end ofZNFSl, fused to 
an Alu element of chromosome 9, was detected. By mutation screening of ZNF81 in 
families linked to Xpl 1.2, a sequence change p.S179N was found in MRX45 υ , that fully 
segregated with the phenotype of non-specific MR. Moreover, this mutation was not 
detected on 451 X chromosomes derived from healthy controls. Mutation analysis was 
extended to 526 MR males, but the five additional sequence changes that were found in this 
population, were all present in healthy controls. The p.S179N though, was only found in 
MRX45 and not in any of the other 525 MR males, which indicates that the p.S179N 
alteration is a rare event in the XLMR population. This is not unexpected since in most of 
the MRX genes mutations have turned out to be very rare 6. This observation suggests that 
ZNF81 is causative for non-specific X-linked mental retardation, however the number of 
controls is not sufficiently large to entire rule out p.S179N being a rare polymorphism 1^ 
Two other mentally retarded female patients with a balanced X;autosome translocation 
have been reported 2 '1 5 where mental retardation appears to be caused by disruption of a 
zinc finger gene on the X-chromosome. In particular, the recent finding by Shoichet et al.2 
that the highly related ZNF41 is responsible for MRX, strongly supports the notion that 
ZNF81 is involved in the cause of MRX as well. 
As described by Ladomery and Dellaire '6, zinc finger proteins are the most abundant class 
of proteins in the human proteome. Zinc fingers are ancient motifs capable of mediating 
interactions with other proteins as well as with DNA and RNA. Almost a third of all Cys2-
His: zinc finger proteins, contain a Krueppel-associated box (KRAB) domain, a 
transcriptional repressor motif that is thought to function through its interaction with the co-
repressor KAP-l17. KAP-1 can interact with the heterochromatin protein HP1 and may 
mediate transcriptional silencing through the recruitment of histone modifying proteins 
such as histone methyltransferases and histone deacetylases '8 ; '9. This implicates that 
KRAB/C2-H2 zinc finger proteins are thought to be primarily involved in gene regulation. 
However, it has been shown that some of these proteins play a role in RNA processing as 
well 20. The multifunctionality of zinc finger proteins is considered to be mediated by 
alternative splicing and sub-cellular compartimentalisation. At present the functional 
diversity of the ZNF81 protein is not known. Interestingly, we found that ZNF81 has, at 
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least in lymphoblasts and in fetal brain, one alternative splice product, lacking the non-
coding exon 2 We searched for mutations in the 5' UTR exons 1 and 2, that might have an 
effect on splicing, but we were not able to identify any such alterations (data not shown) 
The mechanism by which the sequence change is responsible for the mental retardation in 
MRX45 is not clear The ρ S179N is not within a conserved region and it did not have an 
effect on splicing (data not shown) It is known that the amino acid Serine has a potential 
phosphorylation or glycosylation site Asperigine does not have such a position, so the 
ρ S179N change might lead to changes in protein folding or structure 
Another interesting point is that four ZNF genes (ZNF4I, ZNF21, ZNF157 and ZNF81) are 
clustered in Xpl 1 23/pl 1 3 " ' " " It has been postulated that this is the result of duplication 
events that occurred after evolutionary divergence Hence, sequence and functional 
variations in these duplicated proteins may play a role in establishing species- specific 
attributes 2 3 It is of note that we were unable to detect any ZNFSl-Uke transcript in mouse 
brain cDNA using degenerate primers (data not shown) In addition, thorough in silico 
analysis, did not reveal any evidence for a ZNF81 orthologue in mouse, whereas there is 
one for rat The same holds true for ZNF41 As it is well known that rats have significantly 
higher cognitive capacities than mice, it is tempting to speculate that KRAB ZNF proteins 
may partly account for this This study and the recent study by Shoichet et al 2 have 
identified ZNF41 and ZNF81 as genes in which mutations are associated with MRX, which 
would support such role for ZNF genes in cognitive development The question remains if 
the disruption ofZNFtil is solely responsible for the phenotype of the proband in this study 
Since the breakpoint on chromosome 9q34 interrupts another gene as well, Eu-HMTasel, it 
is reasonable to speculate that the disruption of this gene may cause some of the 
dysmorphic features that are associated with the translocation and which are not seen in the 
patients from the MRX family with non-specific MR In addition, we cannot formally 
exclude that disruption of the Eu-HMTasel gene also contributes to the mental handicap in 
the translocation patient, which is significantly more severe than the mild MR in the 
MRX45 family Further studies on the Eu-HMTasel gene need to be performed to clarify 
this 
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3.1 Low frequency OÏMECP2 mutations in mentally 
retarded males 
HG Yntema, Τ Kleefstra, AR Oudakker, Τ Romein, BBA de Vries, WN Nillesen, EA 
Sistermans, HG Brunner, BCJ Hamel, Η van Bokhoven 
Eur J Hum Genet 2002 10(8) 487-90 
A high frequency of mutations in the methyl CpG-binding protein 2 (MECP2) gene has 
recently been reported in males with nonspecific X-linked mental retardation The results of 
this previous study suggested that the frequency of MECP2 mutations in the mentally 
retarded population was comparable to that of CGG expansions in FMRl In view of these 
data, we performed MECP2 mutation analysis in acohort of 475 mentally retarded males 
who were negative for FMRl CGG repeat expansion Five novel changes, detected in seven 
patients, were predicted to change the MECP2 coding sequence Except for one, these 
changes were not found in a control population While this result appeared to suggest a high 
mutation rate, this conclusion was not supported by segregation studies Indeed, three of the 
five changes could be traced in unaffected male family members For another change, 
segregation analysis in the family was not possible Only one mutation, a frameshift created 
by a deletion of two bases, was found to be de novo 
This study clearly shows the importance of segregation analysis for low frequency 
mutations, in order to distinguish them from rare polymorphisms The true frequency of 
MECP2 mutations in the mentally retarded has probably been overestimated Based on our 
data, the frequency of MECP2 mutations in mentally retarded males is 0 2% (1/475) 
Mutations in the methyl-CpG binding protein 2 (MECP2, MIM 300005) gene have first 
been described in Rett syndrome (RTT, MIM 312750), a progressive neurologic 
developmental disorder ' As RTT occurs almost exclusively in females, it has been 
proposed that RTT is caused by an X-linked dominant mutation with lethality in 
hemizygous males However, MECP2 mutations have now been reported in severely 
retarded males with progressive neurological symptoms 2 6, in males with non-progressive 
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encephalopathy 7 and in males with an Angelman-like phenotype 8. Recently, mutations 
have also been described in males from families with nonspecific X-linked mental 
retardation (MRX)9'10. Of all reported MRX genes, MECP2 may have the highest mutation 
frequency. MECP2 mutations that do not cause RTT in females have been found in families 
with X-linked mental retardation that were previously linked to Xq28.5 9 · " . In addition, 
based on an analysis of the MECP2 gene in 185 sporadic MR males, Couvert et al., 9 
suggested that mutations in MECP2 are responsible for approximate 2% of mental 
retardation in males. This indicates that the frequency of MECP2 mutations equals that of 
FRM1 n. 
Table 1: Silent changes and known non-pathogenic variants in 475 MR males 
Nucleotide change Amino acid effect Frequency in this study Reference 
1/475 This study 
l*/475 This study 




1 */475 17 
1/475 This study 
1/475 18 
This hypothesis prompted us to perform MECP2 mutation analysis on the DNA of 475 
mentally retarded males, who were negative for the CGG repeatexpansion in the FMRJ 
gene, and had a normal (46, XY) karyotype. Informed consent was obtained in all 
instances. No pre-selection based on degree of mental retardation and presence of 
additional dysmorphic or neurologic abnormalities was made. We performed mutation 
analysis of the coding region and splice sites of the MECP2 gene by direct sequencing of 
PCR-amplified genomic DNA (five fragments, primer sequences are available upon 
request). 
Fourteen different sequence changes were detected. Of these changes, four were reported 
previously as non-pathogenic variants and five were novel silent changes (Table 1). Five 
changes were possible mutations not described before (Table 2). The latter group included 
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stop codon. The T196S change was found in three patients of different families. Following 
the detection of four novel amino acid changes, we investigated the DNA of 150 control 
males for these changes by allele-specific oligonucleotide hybridization. The T196S 
mutation was found in one of the controls. The other amino acid changes were not detected 
in the control population. Sequence analysis revealed that all mothers of the patients were 
heterozygous (carriers) for the sequence changes. For three amino acid changes segregation 
studies were performed. All changes were found in male family members with normal 1Q, 
including grandfathers, maternal uncles and healthy brothers of the index patients. These 
results indicate that the changes T196S, E394K and P480S are rare polymorphisms instead 
of disease causing mutations. 
A Normal 1415-1416delAG 
A A. 
G O C C H H H C H G H G M G G Û G C C G G C C N H H C U G H G G H G C C 
k ι M ä UM 
D GG.CCA.AAC.AGA.GAG.GAG.CCT.GTG.GAC AGC.CGG.ACG CCC GIG.ACL.GAG.AGA.GI 1.AGC IGA.C WlldtVpe 
Pro Asn Arg Glu Glu Pro Val Asp Ser Arg Thr Pro Val Thr Glu Arg Sor Vil 
GG CCA.AAC AGA GGA.GCC.TGT.GGA.CAG.CCG.GAC.GCC.CGI.GAC.CGA.GAG.AGI.TAG CTG AC 
Pro Asn Arg Gly Ala Cys Gly ala Pro Aap Ala Ar? Aap Arg Glu Ser * 1415-1416del 
Figure 1: Mulation analysis of MECP2 in a patient with moderate mental retardation. (A) PCR products of the 3' 
part of the last exon were sequenced and a deletion of two bases at position 1415 - 1416 (indicated by Δ) was 
detected in the patient (B) Wildtype DNAsequence and predicted protein are shown at the lop. Below the DNA 
sequence and the predicted protein sequence from the patient are depicted. The 13 novel C-lermmal amino acids 
arc shown in italics 
The T228S amino acid change was inherited from the mother, but no other family members 
were available for further segregation analysis. In this case, it is impossible to distinguish 
between a rare non-pathogenic variant and a causative mutation. The threonine at position 
228 however is not conserved in mouse (alanine), rat (alanine) and chicken (glycine), 
indicating that it is unlikely that the change has a dramatic effect on the MECP2 protein. 
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The 1415 - 1416del mutation was found hemizygously in the patient and was absent in the 
DNA of the mother. Thus, this is the first reported de novo MECP2 mutation in a male. 
Somatic mosaicism for a MECP2 mutation in males 2'5 as well as inherited MECP2 
mutations in males have been previously described :,·4·6"l0. The 1415 - 1416del mutation in 
the 3' part of the gene leads to a frameshift and premature stop codon. It is predicted that C-
terminal 15 amino acids are replaced by 13 other amino acids (Figure 1). Previous clinical 
studies showed that the patient has moderate mental retardation (IQ 45 - 55), emotional 
disturbances, gynaecomastia and generalized obesity. Results of clinical re-examination 
will be published elsewhere n . MECP2 mutations in males frequently comprise amino acid 
substitutions or truncating mutations at the C-terminus, outside the conserved MBD and 
TRD domain, like in the patient reported here J·4·7 '9 '". Apparently, these mutations are 
milder than those seen in RTT, very likely because they will affect only a subset of all 
MECP2 target genes. 
Our study supports the finding of Glatt et al., '4 who suggested that rare missense variants 
might be more common than expected. Therefore, it is of crucial importance to perform 
segregation analysis in the families, once a possible mutation has been identified. 
Generally, a control population of males and females is screened for the change. In this 
study, three amino acid changes were found in 1/475 patients (0.2%). Therefore, at least 
1500 chromosomes would need to be examined to determine if the frequency in normal 
males is significantly different from that in patients l5. Furthermore, only male 
chromosomes should be used as a control because MRX acts as a recessive trait and a 
change in a control female could actually cause a phenotype when transmitted to a son. 
Furthermore, it is important that all sequence changes identified worldwide are deposited in 
the MECP2 mutation database (http://homepages.ed.ac.uk/skirmis/). For low frequency 
changes, the most efficient way to distinguish between a polymorphism and a disease 
causing mutation may be segregation analysis in the family 16. The frequency of MECP2 
mutations in the Dutch Fragile-X negative mentally retarded males is 0.2 to 0.4% (the latter 
figure applies if the T228S change is regarded a causative mutation). In our institute, 
expanded CGG repeats in the FMRI gene are detected in 2.5% of an equal population of 
mentally retarded males, ie those mentally retarded males without a family history of 
Fragile-X syndrome (E Sistermans,unpublished observations). 
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MR borderline, IQ 70-85; mild, IQ55-69; moderate, IQ 40-54; severe, IQ 25-39 
ND: not determined 
NA: not available 
The difference between the MECP2 mutation frequency in our study (1/ 475; 0.2 -0.4%) 
and the 2% (4/185) previously obtained by Couvert et ai, 9 is statistically significant 
(P=0.002; Fisher exact test) . Our study revealed the importance of segregation analysis, 
which showed that several possible mutations were polymorphisms. In contrast to the 
present study, the design oft he previous study did not allow contacting additional family 
members and segregation analysis could not be performed. The changes in the previous 
study were not found in 500 control chromosomes, but this amount is too low to exclude 
that some of the putative mutations in that study (eg P399L, R453Q) may in fact be rare 
polymorphisms. 
In conclusion, our results indicate that the incidence of MECP2 mutations in sporadic male 
MR is 5 -10-fold lower than that of Fragile-X syndrome. 
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Abstract 
Rett syndrome (RTT) is one of the most common neurodevelopmental disorders in females. 
The disease is caused by mutations in the Methyl-CpG-binding protein 2 gene (MECP2) 
and various mutations have been reported. The phenotypic spectrum in both female and 
male patients is diverse, ranging from very mild to congenital encephalopathy and prenatal 
lethality In this study the question was addressed whether implementation of systematic 
screening of MECP2 in patients with an unexplained mental retardation in DNA 
diagnostics would be reasonable and the spectrum of phenotypes resulting from mutations 
in this gene was further explored Mutational analysis of MECP2 was performed in 
mentally retarded female patients who were negative for FMR1 CGG repeat expansion, in 
male and female patients with clinical features suggestive of either Angelman or Prader-
Willi syndrome without methylation defects on chromosome 15ql l-ql3 
In the cohort of females negative for the molecular Fragile-X studies (N= 92) one nonsense 
mutation (p Q406X) was found. In the cohort of Angelman-negative patients (N=63) two 
missense mutations (p.R133C in a female patient and a mosaic p.T158M in a male patient) 
were found, that have been reported many times in patients with classical RTT syndrome. 
In the Prader-Wilh-negative group (N=98), no pathogenic mutations were found 
The results support testing of patients with features suggestive of Angelman syndrome but 
without methylation defects on chromosome 15ql l-ql3 for mutations in MECP2 In the 
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remaining patients with unexplained mental retardation (MR), additional clinical features 
should determine whether analysis of MECP2 is indicated. 
Introduction 
Heterozygous mutations in the X-linked MECP2 gene have first been reported in Rett 
syndrome (RTT), a progressive neurologic developmental disorder, occurring almost 
exclusively in females '. In approximately 95% of patients these mutations occur de novo 
and it has been shown that in most cases they are of paternal origin 2. 
Recent studies indicate that females with RTT appear to represent a more heterogeneous 
phenotype than was first realized 3"5. There are cases with a very mild phenotype, with 
preserved speech variant or with a congenital, early seizure onset. It is hypothesized that 
these differences are mainly due to the genotype, variation in X-inactivation patterns and 
probably other polygenic modifiers 3'6. 
Unlike previous thoughts, MECP2 mutations are not necessarily prenatally lethal in males 
and are the cause of a variable phenotype, ranging from lethal congenital encephalopathy to 
Angelman-like phenotype and mild non-specific X-linked mental retardation (MRX) 7"'2. 
Because the complete phenotypic spectrum of MECP2 mutations in both male and female 
patients is presently unknown, more studies are required. Previously, we reported on 
MECP2 mutation analysis in a cohort of 475 mentally retarded males who were negative 
for FMRI CGG repeat expansion and found one mutation that correlated with a Prader-
Willi-like phenotype ' 3 · ' 4 . It was suggested that MECP2 might have a role in regulating 
genes involved in body habitus. Since some patients with features of Angelman syndrome 
also had mutations in the MECP2 gene (10,11), genes in the region 15qll-13 could be 
target genes downstream of MECP2. Therefore it was suggested that it was worthwhile to 
evaluate the prevalence of MECP2 mutations among patients with features suggestive of 
the Prader-Willi syndrome but without the characteristic molecular abnormalities on 
chromosome 15q. 
To answer the question whether implementation of systematic screening of MECP2 in 
patients with an unexplained mental retardation in DNA diagnostics would be reasonable 
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and to explore further the spectrum of phenotypes resulting from MECP2 mutations, we 
performed mutational analysis in three additional patient groups in mentally retarded 
female patients (N=92) who were negative for FMRl CGG repeat expansion, in male and 
female patients with a phenotype suggestive of Angelman syndrome (N=63) without 
methylation defects in chromosome 15qll-ql3 and in male and female patients with a 
phenotype suggestive of Prader-Willi syndrome (N=98) also without methylation 
abnormalities on chromosome 15ql l-ql3 
Subjects and Methods 
Patients 
The patients had been referred to our DNA diagnostic division during the last 5 years The 
patients were subdivided in three panels according to their previous request for DNA 
testing for Fragile-X syndrome, Angelman syndrome or Prader-Willi-syndrome The panels 
were called Fragile-X-negative (92 female patients), Angelman-negative (30 females and 
33 males) or Prader-Wilh-negative (41 females and 57 males) If the patient's DNA had 
been analysed for Angelman syndrome or Prader-Willi syndrome and Fragile-X syndrome, 
the patient was included in the Angelman- negative or Prader-Willi-negative panel For all 
patients informed consent was obtained 
DNA analysis 
DNA was extracted from peripheral blood as described previously '5 The three coding 
exons of MECP2 were amplified using PCR and genomic DNA as a template Both strands 





X-inactivation studies were carried out on DNA isolated from lymphocytes from the 
p.Q406X patient as 
Described by Allen et al. '6. However, the analysis was performed on an automated 
sequencer (ABl 3100 Prism) in stead of Southern hybridisation. 
Results 
DNA studies 
The results of mutation analysis of all three panels are shown in table 1 a and 1 b. In the 
Fragile-X-negative panel, two sequence changes were found, one known polymorphism 
C.1126C—>T (p.P376S) and one nonsense mutation C.1216C—>T (p.Q406X). The mutation 
was not found in the parents. X-inactivation studies in the patient lymphocytes showed a 
100% skewed pattern. 
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In the Angelman-negative group, two known pathogenic missense mutations were found, 
C.397C—>Ί (p.R133C) in a female patient and a mosaic C.473G—>T (p.T158M) in a male 
patient and one novel change c. 1497G—»C in a female patient. The C.1497G—>C is in the 3' 
UTR of the gene and was found also in the mother of the patient. The known polymorphism 
c l 126C—>T (p.P376S) was also found in this cohort in a female patient and in her father. 
The p.R133C was not found in the mother. The mother of the male patient with the mosaic 
p.T158M mutation did not have this mutation. 
In the cohort of Prader-Willi-like patients one novel silent change c.393 C—>G (p.A131A) 
was found. 
Clinical studies of patients with a MECP2 mutation 
P.Q406X 
This girl was bom at term after an uneventful pregnancy and delivery with a birthweight of 
2550 grams. During early life she was a passive baby. Psychomotor development was 
delayed, she walked at 3 years and spoke her first words at the age of 5 years. She had no 
EEG abnormalities. 
At the age of 16 years she attended an institute for child-psychiatry because of behavioral 
problems. The degree of mental retardation was moderate. Chromosomal analysis and DNA 
studies of the Fragile-X syndrome were normal. 
At the age of 22 years she was re-examined Her height was 160 cm (-1.5 SD), her weight 
was 57 kg (0 SD) and her skull circumference was 56 cm (0.5 SD). She had a face with a 
child-like appearance and a strabismus of the left eye. She spoke with short sentences. Her 
gait was slightly unsteady. 
P.R133C 
This girl was bom at term after an uneventful pregnancy and delivery with a birthweight of 
3500 grams. After 6 months of normal development there was developmental stagnation 
and only a slow further progression. No developmental regression was noted. She walked at 
24 months and spoke her first words at 5 years of age. 
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Figure 1: Female palienl with the p.R133C mutation in MECP2 at 
the age of 14 years. 
On investigation at the age of 7 years she had normal height and head circumference and 
was slightly obese. She was a severely retarded, friendly and happy person and spoke with 
two-words sentences. She showed teeth grounding and had a wide based gait. She was 
insensitive to pain. Since the age of 7 years there were severe sleep disturbances. Daytime 
EEG studies showed epileptic activity in less than 1%, whereas during night more than 75% 
disturbed EEG patterns were observed. In spite of EEG abnormalities, no convulsions had 
been observed. 
Routine chromosomal studies and molecular studies of the Angelman syndrome were 
negative. 
At the age of 14 she was examined again (figure 1). She was a friendly person with growth 
retardation (height of 137 cm (< -2.5SD)), generalised obesity (weight of 60 kg (> +2SD)) 
and hypotonia. Head circumference was 53.5 cm (-1SD). She revealed the same signs as 
discussed above. Moreover, thoracic scoliosis, cold extremities and tapering of the fingers 
were noticed. Her gait was unsteady and wide-based but she could walk and climb stairs 
unaided. In addition, although with some spilling she was able to eat and drink. 
P.T158M 
This boy was bom after an uneventful pregnancy and delivery with a birth weight of 3440 
grams. The first year of life, he developed completely normal. Thereafter his development 
stagnated followed by a period of regression. 
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Figure 2: Male patient with the p.T158M mosaic mutation in MECP2 at the 
age of 11 years. He shows the classical Rett syndrome phenotype. 
He lost his capability of purposeful handuse and walking along the table. At the age of two 
years and nine months, he was a passive boy with autistic features and hardly any speech. 
Stereotypic movements like handclapping and teeth grounding were noted. There were 
convulsions and diffuse EEG abnormalities. Later on he developed periods of yelling and 
shouting and sleeping disturbances. No metabolic defects were found. Routine 
chromosomal studies and DNA studies of the Angelman- and Fragile-X syndrome were 
normal. At the age of eleven years he was re-examined (figure 2). He had a weight of 11 kg 
(-2 SD) and a skull circumference of 51.5 cm (-2 SD). His height was not measured. In 
addition to the previous features, he was wheelchairbound and a severe thoracic scoliosis 
was observed. Feet were small and cold. 
Discussion 
We report on three large patient cohorts in which MECP2 mutation analysis was performed 
to ascertain whether routine screening of this gene in patients with unexplained MR in a 
DNA diagnostics setting is indicated and to further explore the phenotypic spectrum of 
MECP2 mutations. 
In the cohort of females negative for the molecular Fragile-X studies we found two 
nucleotide changes. The nonsense p.Q406X mutation that was found in this cohort has been 
reported once in a family where both the maternal uncle and son had mental retardation and 
spasticity . The two carrier females had a borderline intelligence, but no other symptoms. 
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X-inactivation in these two carriers showed random patterns. In our patient however the 
mutation was de novo. She was moderately retarded, had EEG abnormalities, behavioural 
problems and autistic features without spasticity. Differences in these two phenotypes 
might be explained by differences in the X-inactivation patterns or by currently unknown 
genetic modifiers. X-inactivation analysis in this patient showed completely skewed X-
inactivation. Unfortunately, it was not possible to analyse which allele was the active or 
inactive one, but most likely the normal allele was inactivated. This might explain why 
heterozygosity of the p.Q406X in our patient leads to a severe phenotype whereas in the 
two other individuals it results in a nearly normal phenotype. Since X-inactivation is 
performed in lymphocytes, it will not be conclusive for X-inactivation in brain cells. 
Therefore, the question still remains whether the differences in the two phenotypes is 
explained by X-inactivation differences. The other nucleotide change that was found in this 
cohort (p.P376S) has been reported as a polymorphism 4. 
In the cohort of 63 Angelman-negative patients we found three nucleotide changes. Two 
changes were known missense mutations, one p.R133C and one mosaic p.T158M. The de 
novo P.R133C mutation has been reported many times in patients with classical RTT 
syndrome (http//www.ed.ac.uk—skirmis-). Though our patient did meet several criteria for 
classical RTT syndrome, there was no history of regression, she did not have the acquired 
microcephaly and stereotypic handmovements. In addition, she showed extreme obesity 
while most RTT patients have decreased body fat. Because of this atypical appearance of 
Rett syndrome, this clinical diagnosis was not considered initially. 
The P.T158M mutation found in mosaic form in a severely retarded male patient is a 
frequently reported mutation in classic RTT syndrome as well. The percentage of mutant 
versus wildtype allele was estimated to be 25%. Since this is analysed in lymphocytes, it is 
uncertain whether in brain tissue this percentage will be equal. In males this mutation has 
been reported in a Klinefelter syndrome patient '7 and post mortem in two brothers with 
congenital encephalopathy 8. Males with other mosaic MECP2 mutations have been 
reported as well '8'<'. Since they all exhibit features of classic RTT syndrome it is suggested 
that a MECP2 mutation associated with RTT syndrome in females could lead to a similar 
phenotype in males as a result of somatic mosaicism. The clinical diagnosis of Rett 
syndrome was considered previously, but it was believed at that time that this syndrome did 
not occur in males. 
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The C.1497G—>C that has not been reported so far, was in the 3' UTR of the gene and was 
also found in the mother of the patient Therefore, this change is considered a 
polymorphism. 
Finally, in the panel of Prader-Wilh-negative patients, one silent change in the coding 
sequence was found Although this change has not been reported so far, it is unlikely to 
have a pathogenic effect. 
In female patients with unexplained MR but without features of classic RTT syndrome, the 
mutation detection rate found here is 1/92 It is believed that the X-inactivation patterns 
observed in patients with RTT syndrome show a standard distribution The percentage of 
possible cases with a MECP2 mutation on both tails of the distribution (neonatal death 
versus mild neurologic/cognitive defects) is expected to be very low and therefore difficult 
to find 3 '8. A routine search for MECP2 mutations in female patients with unexplained MR 
without features of classical Rett syndrome, therefore might not be worthwhile 
In the Angelman-negative cohort our mutation rate (2/63) is lower than the ones found by 
Imessaoudene et al. (6/78) ' ' and Watson et al (5/47) 7 Although the patient cohorts in 
these studies were possibly clinically better defined than in the present study, our results 
still indicate that MECP2 mutational analysis in patients with a clinical diagnosis of 
Angelman syndrome but without molecular abnormalities on chromosome 15qll-ql3, is 
worthwhile. 
Recently we suggested that MECP2 might have a role in regulating genes involved in body 
habitus lA Since some patients with features of Angelman syndrome also had mutations in 
the MECP2 gene 7 ", genes in the region 15qll-13 might be target genes downstream of 
MECP2. Therefore we evaluated the prevalence of MECP2 mutations among patients with 
features suggestive of the Prader-Willi syndrome but without the characteristic molecular 
abnormalities on chromosome 15q 11 -q 13 However based on the current studies, routine 
screening of MECP2 in Prader-Willi-hke patients might not be worthwhile, since we only 
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gynaecomastia 
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Abstract 
Rett syndrome (RTT) is an X-linked neurodevelopmental disorder caused by mutations in 
the MECP2 gene, with apparent lethality in male embryos However recent studies indicate 
that mutations in the MECP2 gene can cause congenital encephalopathy, Angelman like 
phenotype and even non-specific mental retardation in males 
We report on a 10 years old boy with moderate mental retardation, hypotonia, obesity and 
gynaecomastia and a de novo two-bp deletion in the MECP1 gene that resulted in a 
frameshift and premature stopcodon. As some of the clinical features were suggestive the 
Prader-Willi syndrome, it might be worthwhile to screen for MECP2 mutations in patients 
with an atypical Prader-Willi phenotype, but without the characteristic abnormalities on 
chromosome 15q. 
This report contributes to the phenotypic knowledge of male patients with MECP2 
mutations Moreover, this is the first reported male case of ade novo MECP2 mutation 
Introduction 
Heterozygous mutations in the X-linked MECP2 gene were first reported in Rett syndrome 
(RTT), a progressive neurologic developmental disorder, occurring almost exclusively in 
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females. Diagnostic criteria for RTT were established by Hagberg et al., '. In RTT, 
mutations in MECP2 have been described with a detection rate of 25%-80% 2·3. In 
approximate 95% of cases these mutations occur de novo they are almost exclusively of 
paternal origin ". 
Recent studies indicate that MECP2 mutations are not necessarily prenatal lethal in males, 
but are the cause of lethal congenital encefalopathy 5 ·6 and even of non-fatal 
encephalopathy 7'13. This latter group comprises patients with a variable phenotype ranging 
as diverse as Angelman-like phenotype to mild non-specific X-linked mental retardation 
(MRX). Because the complete phenotypic spectrum of these male patients is presently 
unknown, it is important to acquire more knowledge. In this report the clinical and 
molecular features of a male patient with a MECP2 mutation are presented and compared 
with previous reported cases. 
Materials and Methods 
DNA studies 
The patient's DNA was examined in a large screening for MECP2 mutations in a cohort of 
500 males with non-specific X-linked mental retardation (Yntema et al., submitted). For 
this study DNA was extracted from peripheral blood as described previously '4. MECP2 
mutation analysis was performed by direct sequencing of polymerase chain reaction (PCR)-
amplified genomic DNA. 
Results 
Clinical report 
The propositus was bom at term after an uneventful pregnancy and delivery with a 
birthweight of 2950 g. He was the only child of healthy parents. Early motor milestones 
were normal: he sat without support at 7 months and walked at 16 months of age. His 
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language development was delayed, he spoke his first words at the age of 2 years. When he 
was 3 years old, he developed absences, for which he received antiepileptic medication for 
2 years. After this period no more seizures appeared. 
Because of concentration disturbances and socio- emotional lability, he attended a school 
for special education where mental retardation was diagnosed. 
At the age of 8 years, he was in a clinic for child behavior disorders for a period of 6 
months to ascertain the degree of the mental retardation and the status of socio-emotional 
problems. Several investigations were performed, including psychodiagnostic, neurological, 
ophthalmological, chromosomal and fragile X studies. 
On neurological examination an agitated boy with hypotonia and weak motorskills was 
observed. Diffuse cerebral disturbance with predominance of the left hemisphere was 
reported. Electroencephalography (EEG) showed left centro-temporal epileptic activity, 
although no convulsions had been seen since the age of 5 years. The degree of mental 
retardation was assessed as moderate (IQ 45-55) and his socio-emotional behaviour was 
very weak. 
Figure 1 :Prospositus at the age of 10 years. Note obesity and 
gynaecomastia 
On ophthalmological examination convergent strabismus and mild hypermetropia were 
found. 
Chromosomal studies and DNA analysis of the fragile X syndrome were normal. At 10 
years of age he was an easily distracted boy, with gynaecomastia and generalized obesity 
(Fig.l). He had a height of 145 cm (-1SD), a weight of 47 kg (+2SD) and a head 
circumference of 51.5 cm (-1SD). His handlength was 15.5 cm (P25) and finger 111 length 
5.9 cm (P3). 
87 
Chapter 4 
He had short moments of typical breath holding (gasping). Facially he showed a short 
forehead, short philtrum, full lips and simple ears. His black, brushy eyebrows and 
eyelashes are noted in the father as well. The grandparents from father's side were from 
different ethnic background. 
He had a short neck with a low hairline. Clinodactyly and shortness of the fifth digit and 
tapering of all fingers were noted. The feet had clinodactyly of the second digit, partial 
cutaneous syndactyly between the second and third digit and outward position of the nail of 
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Figure 2: Schematic drawing of the MECP2 gene. The regions encoding the Methyl Binding Domain (MBD), 
Transcription Repression Domain (TRD) and C-tcrminal (C-ter) part are indicated. 
The arrows point the position of the mutations from table 1. 
DNA studies 
Sequencing analysis revealed a deletion of 2 bases at position 1411-1412 of the MECP2 
gene (141 l-1412delAG) and was not present in the mother. This de novo mutation at the 3' 
part of the gene leads to a frameshift and premature stop codon. It is predicted that the 16 
amino acids that normally follow this position in the protein, are replaced by 14 other 
amino acids. 
88 
Table 1 Previously presented male patients with their respective MECP2 mutations 





Congenital encephalopthy (death at birth) 
l)Movement disorder, resting tremors 
2) Moderate non specific mental retardation 
Moderate non-specific mental retardation 
Moderate non-specific mental retardation, 
obesity 








Present case 1411 del2bp 
Moderate non-specific mental retardation 
Moderate non-specific mental retardation 
Congenital encephalopathy (death at birth) 
Congenital encephalopathy (death< 2 years) 
Angelman-like 
Non-specific mental retadrdation 
Progressive spasticity 
Mild dysmorphisms, hypotonia, obesity, 
gynaecomastia, moderate mental retardation 
Sister with RTT, two brothers 
Mother and daughter (mild) 
and 4 sons (severe) 
no segregation tested 
Villard et al 
Omco et al 
Couvert et al 
MRX 16 family, 5 affected males in two generations Couvert el al. 8 
4 affected males in two generations 
Somatic mutation 
No segregation tested 
No segregation tested 
Sister with RTT 
Two affected males 
No segregation tested 
Maternal uncle and nephew 
Maternal uncle and nephew 
De novo 
Couvert et al 
Clayton-Smith et al 
Couvert et al 
Couvert et al 
Wan et al 
Hoffbuhr et al 
Imessaoudene et al 
Yntema et al 
Meloni et al 




We report on a male case with a MECP2 mutation responsible for moderate mental 
retardation, emotional disturbances and characteristic clinical features. 
Twelve previously reported MECP2 mutations in males resulted in either fatal congenital 
encephalopathy (three) or in non-fatal encephalopathy (nine), table 1 and figure 2. 
However, since in several cases family studies could not be performed, the possibility of 
polymorphisms is still open. Three of the reported mutations: one mosaic 2-bp deletion and 
two missense (one of them reported twice), were found in the region encoding the Methyl 
Binding Domain (MBD) 5·8·'5, one was between the MBD and Transcription repression 
Domain (TRD)8, one was within the TRD 7 and seven were found in the region encoding 
the C terminal part (Cter) 6·9""·13: one nonsense, four missense and two deletions. The 
phenotype of the patients with Cter mutations is quite diverse. The 80 amino acids deletion 
in both patients reported by Yntema et al. I3 is in frame which might explain the mild 
mental retardation in the patients of this family. The 32-bp deletion however resulted in a 
premature stopcodon and a severe, lethal phenotype . The point mutations in Cter all 
resulted in non specific mental retardation. A Comparison of our patient to these cases 
reveals that none fits a specific phenotype. Nonspecific features as behavior characteristics, 
hypotonia, spasticity or ataxia seem the most prevalent signs among the patients. 
Of the 13 cases, segregation analyses of the MECP2 mutation in the respective families has 
been performed in 9 of them. In all these cases, except for the somatic mosaic, the mothers 
of the affected patients were carriers of the MECP2 mutation. The mutation presented here 
was not found in the mother and is therefore the first reported de novo MECP2 mutation in 
a male patient. Trappe et al. 4 however, found that de novo MECP2 mutations in female 
patients with Rett syndrome were almost exclusively of paternal origin. It has been 
suggested that the maternal allele is less prone to de novo MECP2 mutations than the 
paternal allele. However the current case is an example that de novo MECP2 mutations can 
occur on the maternal allele. 
A characteristic feature of the current patient is the obesitas. Obesity has also been observed 
in three of the four patients with MECP2 mutation and non-specific mental retardation of 
the family reported by Couvert et al. 8. Although our patient does not have a classical 
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Prader-Willi syndrome phenotype, the combination of hypotonia, mental retardation, 
hypotonia and obesity, is seen in patients with the Prader-Willi syndrome. Although the 
obesity in the four patients could be a coincidental finding, it may suggest a role of MECP2 
in regulating genes involved in body habitus. As some patients with features of Angelman 
syndrome also had mutations in the MECP2 gene '6, it has been suggested that genes in the 
region 15qll-I3 might be target genes downstream of MECP2. Therefore it might be 
worthwhile evaluating the prevalence of MECP2 mutations among patients with features 
suggestive of the Prader-Willi syndrome but without the characteristic molecular 
abnormalities on chromosome 15q. 
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4.2 Genotype-phenotype studies in three families with 
mutations in the Polyglutamine-Binding Protein 1 gene 
{PQBP1) 
Τ Kleefstra, CE Franken, YHJM Arens, GJA Ramakers, HG Yntema, EA Sistermans, 
CFCH Hulsmans, WN Nillesen, H van Bokhoven, BBA de Vries, BCJ Hamel 
Clin Genet 2004 66(4) 318-326 
Abstract 
Recently, the polyglutamine-binding protein 1 gene (PQBP1) was found to be mutated in 5 
out of 29 families studied with X-linked mental retardation (XLMR) linked to Xp The 
reported mutations include duplications or deletions of AG dinucleotides in the fourth 
coding exon that resulted in shifts of the open reading frame. Three of the five families with 
mutations in this newly identified XLMR gene have been reported previously. 
We characterized the phenotypic and neuropsychological features in the two unpublished 
families with aberrations in PQBP1 and in a family reported ten years ago In total 7 
patients diagnosed with aberrations in this gene were examined including a newly identified 
patient at 18 months of age. Additionally, the features were compared to those reported in 
the literature of three other families, comprising MRXS3 (Sutherland-Haan Syndrome, 
SHS) MRX55 and MRXS8 (Renpenning syndrome) Characteristics seen in these patients 
are microcephaly, lean body habitus, short stature, striking facial appearance with long 
narrow faces, upward slant of the eyes, malar hypoplasia, prognathism, high-arched palate 
and nasal speech In addition, small testes and midline defects as anal atresia or imperforate 
anus, clefting of palate and/or uvula, ins coloboma and Tetralogy of Fallot are seen in 
several patients. 
These observations contribute to the phenotypic knowledge of patients with PQBP1 




X-linked mental retardation (XLMR) is classically divided into syndromal (MRXS) and 
non-syndromal (MRX) forms, depending on the presence or absence of specific 
distinguishing clinical, morphological, neurological or metabolic anomalies. At present 
there are more than 30 genes identified that play a role in MRXS, whereas for MRX, only 
15 causative genes are known l"6. The recent observations that RSK2, MECP2 and ARX 
play a role in both syndromic and in non-syndromic forms of XLMR 7"'0, suggest that there 
is no molecular basis for strictly separating these two forms. In addition, careful clinical re-
examination of patients with an OPHN1 gene mutation has revealed distinctive phenotypic 
hallmarks, such as cerebellar hypoplasia, in patients, which were previously, classified as 
non-syndromic ""l3. 
Recently, the polyglutamine-binding protein 1 gene (PQBPÌ) was found to be mutated in 5 
out of 29 families studied with X-linked mental retardation linked to Xp 4. Mutations were 
found in families reported as non-specific XLMR (MRX55) '4, as well as in syndromal 
XLMR patients (Sutherland Haan syndrome and Hamel syndrome) '5''6. In addition, lately 
mutations in PQBP1 have been identified in patients with Renpenning syndrome as well23. 
In order to better define the phenotypic spectrum of patients with PQBP1 mutations, we 
clinically (re-)investigated 7 patients from three of the five families with PQBP1 mutations 
and compared them to the features reported in the literature of the other three families, 
comprising MRXS3 (Sutherland-Haan Syndrome, SHS) MRX55 and MRXS8 (Renpenning 
syndrome). 
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Patients and methods 
Families 
The families had been ascertained initially in 1981 (N40), 1984 (N45) and 1989 (N9), when 
they were referred for genetic counselling because of the presence of several mentally 
retarded males. The pedigrees of families N45, N9 and N40 are shown in figure 1A-C. 
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Figure 1 Pedigrees of the families N45 (A), N9 (Β) and N40 (C). 
Affected individuals are referred in the text as case numbers corresponding lo Ihose indicated in the pedigrees 
Psychometry 
Mental retardation is defined as significant sub average general intellectual functioning (IQ 
< 70) (criterion A), significant limitations in adaptive functioning (criteria B) and onset 
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before age 18 (criterion C) '8. To determine the level of intellectual functioning, all patients 
were psychometrically assessed by using at least one of the three highly standardized tests; 
(1) the Wechsler Intelligence Scale for Children-Revised (WISC-RN) l 8 (2) the Wechsler 
Preschool and Primary Scale of Intelligence-Revised (WPPSI-R) '9, and the (3) Snijders-
Oomen Non-verbal Intelligence test 2Ί2-Ι (SON2l/2-7) '9. Adaptive functioning was 
examined by the Adaptive Functioning Scale for Mentally Retarded 20'21. 
Results 
Clinical report 
A summary of the physical measurements, clinical symptoms and psychometric studies are 
summarised in tables I, II and III, respectively. The clinical features of the families with 
SHS and Renpenning syndrome, are included in table II. Data on families MRX55 and the 
second family reported by Lenski et ai, were too limited to include in the table. Facial 
characteristics of affected patients are shown in figures 2-4. 
Mutation analysis 
In affected males and carrier females, exon 4 of PQBP1 that contains a stretch of six AG 
dinucleotides in the DR/ER repeat was amplified using genomic DNA as a template. The 
PCR product was subsequently sequenced as described previously4. 
In all affected males of family N45 two AG dinucleotides are deleted, whereas in family N9 
all affected males carry an extra AG dinucleotide. A single AG unit is deleted in affected 
males from family N40. In all families, the mutations were present in all obligate female 
carriers. These findings were reported previously 4. In addition, in family N9, the extra AG 
dinucleotide was also present in a boy of 18 months of age. In the same family prenatal 
testing of this mutation was performed on a chorion villi sample of a male fetus, who did 
not have the mutation. In family N45, three additional females (II-2, II-9 and II-l 1) turned 
out to be carriers of the familial mutation. 
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52 5 (-3 SD) 
53 4 (< -2 5 SD) 
54.0 (-2.5 SD) 
51 5 (-3.5 SD) 
50.3 ( -4 SD) 
42.0 ( -4 SD) 
50 (< -4 SD) 
Height 
(cm) 
169 (-2 SD) 
180 (-0 5 SD) 
177 (-1 SD) 
164 (-2 5 SD) 
175 (-1 SD) 
76 (-2.5 SD) 
162 (-3 SD) 
Weight 
(kg) 
49.4 (-2 SD) 
53.3 (<-2 SD) 
60 (0 SD) 
54 (0 SD) 
50 (-2 SD) 
10(0 SD) 





(<1 0/0 SD) 
20 5/11 









(-0.5/-0 5 SD) 
Ear Length 
(cm) 
6 5(+l 5 SD) 
7 0 (+2 SD) 
7.0 (+2 SD) 
7 5 (+2 SD) 
5 5(-l SD) 
4.5 (-1 SD) 
6 5(+l 5 SD) 
N45(figure1A) 
Case 1 (II-8, figure 2) 
The patient was bom to healthy non-consanguineous parents. He was bom with a situs 
inversus totalis, but additional clinical data are lacking. 
On examination at the age of 50 years a friendly, severely mentally retarded person was 
seen. He had nasal speech, slender posture, microcephaly, long narrow face with malar 
hypoplasia, upslanting palpebral fissures, protruding ears, and a high-arched palate with 
small uvula. His genitals were normal. 
Case 3 (III-3, figure 2) 
The patient was bom after an uneventful pregnancy and delivery with a birth weight of 
3000 grams (<10th centile). Early developmental milestones were delayed; he started 
walking at 20 months of age, after he was treated with a plaster cast for hip dysplasia, and 
started talking at three years of age. His medical record revealed that examination at this 
age showed microcephaly, large protruding ears, abnormal EEG and no abnormalities seen 
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on cerebral CT-scan or EMG studies. On examination at the age of 25 years, a friendly, 
moderately retarded male with slender posture, brachymicrocephaly and nasal speech was 
seen. He had a long narrow face with high arched palate, large ears and prognathism, 
slender hands and feet and normal genitals. His trunk showed abundant acne. 
Case 2 (11-10, figure 2) 
There are no historical data available about early life, except that this patient was bom with 
anal atresia, for which he was operated soon after birth. He started walking at 20 months of 
age. 
On examination at the age of 47 years, a friendly, moderately mentally retarded patient was 
seen with slender posture, microcephaly, and nasal speech. He had a long, narrow face with 
malar hypoplasia, high arched palate and small uvula, prognathism, mild thoracic scoliosis, 
slender hands, and normal genitals. 





























Levels of mental and adaptive functioning 
mild; 1Q range 50/55-70 
moderate; IQ range 35/40-50/55 
severe; IQ range 20/25-35/40 



















Genotype-phenotype studies in XLMR: from genes to families 
Figure 2: Photos of the affected males Figure 3; Photos of the affected males from 
from family N45. Note long narrow family N9. Note long narrow faces in cases 4 
faces in all individuals, brachycephaly and 5, up ward slant of eyes in case 4 
in case 3, up-ward slant of eyes in case brachycephaly, maxilla hypoplasia and 
1, maxilla hypoplasia in all three prognathism in case 5. Case 6 shows a 
individuals and prognathism in cases 2 rounded face, compare to case 8. 
and 3. 
N9 (figure IB) 
Case 4 (II-l, figure 3) 
This patient was bom at term to healthy non-consanguineous parents with a birth weight of 
2200 grams (< 3rd centile). No other data from his early life were available. 
At age 39, prostatectomy was performed because of recurrent urine retention. Since 50 
years of age, he has mild bilateral sensori-neuronal hearing loss. At age 58, a cerebral CT-
scan showed mild dilatation of both hemi-ventricules relating to central atrophy. 
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On examination at the age of 62 years, a friendly severely mentally retarded microcephalic 
male patient was seen. He spoke in short sentences with nasal sound. A high-arched palate 
with bifid uvula and upward slant of the eyes were noted. Ears were large and protruding, 
extremities and genitals were normal. 
Case 5 (HI-4, figure 3) 
The patient was bom after a pregnancy that was complicated by fluxus at 2 months 
gestation and pyelitis at 32 weeks gestation. Delivery was at term with birth weight of 2250 
grams (< 3rd centile) and length of 48 cm. From 7 months to 12 months of age, he was 
hospitalized to investigate his psychomotor and growth retardation. At this age, an iris 
coloboma of the left eye and a bifid uvula were seen. He started walking at 17 months of 
age. Because of submucuous cleft palate and pharyngeal insufficiency, he underwent 
pharyngoplastic surgery at the age of 5 years. Thereafter, he started to speek more properly. 
A cerebral CT-scan at the age of 16 years did not show (gross) abnormalities. 
On examination at the age of 30 years, a friendly moderately retarded, brachymicrocephalic 
male patient with slender posture and nasal speech was seen. He had a long and narrow 
face with malar hypoplasia, high-arched palate, small uvula, prognathism, small ears and 
an iris coloboma of the left eye. His hands and feet were slender. 
Case 6 (IV-I, figure 3) 
This youngest patient diagnosed with a PQBP1 mutation was bom at term after an 
uneventful pregnancy and delivery with a birth weight of 3000 grams (10lh centile), and a 
skull circumference of 32.5 cm (-2 SD) His development was somewhat retarded, at 18 
months of age he walked at hand and spoke a few words. Examination at this age showed a 
round face, downslanting palpebral fissures and high arched palate, normal extremities and 
genitals. 
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Figure 4: Photos of the affected males from family N40, ease 8 at the age of 33 years (left) and 7 months (right) 
respectively. Note long narrow face and prognathism in case 8, up-ward slant of eyes and maxilla hypoplasia in 
both cases. 
Case 8 shows a rounded face at young age, compare to case 6. 
N40 (figure 1C) 
Case 7 and 8 (III-l, III-3, figure 4) 
Patients 7 and 8 (figures) have been reported by Hamel et al '5. Briefly, the two brothers 
and their two maternal uncles were known with profound mental retardation. Tetralogy of 
Fallot, cleft and/or high arched palate, short stature, microcephaly, abnormal ears, 
upslanting palpebral fissures, bulbous nose, broad nasal bridge, malar hypoplasia and 
micrognathia. On figure 4, patient 7 is 11 years old. Some months later he died because of 
aspiration. 
At age 25, patient 8 was diagnosed with a metastasized testes tumor (embryonic cell 
carcinoma) for which he underwent hemicastration followed by extirpation of lymphenodes 
from internal organs and radiotherapy. After 5 years he was considered completely cured. 
On examination at age 33, he showed the same signs as described before. There were mild 
contractures of elbow and knees, though he neither showed hypertonicity nor spasticity. 
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Data of families MRX55 and second family reported by Lenski el al., were too limited to include in the 
table with selected measurements in 14 males was included. In addition, clinical follow-up of 5 out of 
characteristics. 
NT= Not Tested 
Tetralogy of Fallot 
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3/33 borderline (9%) 
1/33 mild (3%) 
7/33x moderate (21%) 
20/33 severe (60%) 

















table. Data from the Renpenning family were derived from the report of Stevenson el al., (25) in which one 
14 of these affected individuals had been described more detailed in this report, especially with regard to facial 
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There was no progression noted in the severity of clinical symptoms compared to the 
findings of 10 years earlier. 
The obligate carriers 
Five female carriers (N45:II:2 and 11:7; N9: 11:5 and 111:3; N40 11:3) available for 
examination showed all normal academic performances (intelligence was not yet formally 
assessed). They did not show facial abnormalities, although head circumferences were on 
the small side ranging from 52 cm (-2 SD) in III-3 (N9) to 58 cm (+1-2 SD) in II-2 (N45). 
Carrier II-3 (N40) had a succesfull surgical correction of an atrial septal defect at age 22. 
Discussion 
Seven patients from three unrelated families with different ages carrying PQBP1 mutations 
were examined to fiirther evaluate the clinical phenotype of patients with mutations in this 
gene. In all patients microcephaly was observed, which seems to be the main clinical 
symptom in our families. Moreover all adult affected males had a lean body habitus, 
distinctive facial appearance with long narrow facies, malar hypoplasia, prognathism, high 
arched palates and nasal speech. Besides these features realtively large ears and hands and 
feet have been noted in several patients. Three patients had clefting of uvula and/or palate. 
Additional midline defects include complete situs inversus in one patient, iris coloboma in a 
second, anal atresia in a third and Tetralogy of Fallot in two affected males from family 
N40. As has been reported in family N40 4, the phenotype changes with age. Especially the 
change in the shape of the face from round in early childhood to long and narrow at older 
age, was observed in several patients. Case 6, who was 18 months at examination, clearly 
shows a more rounded face than observed in the adult patients. A photograph of case 8 at 
age 7 months (figure 4) compared to the one at older age, illustrates this changing facial 
phenotype in N40. 
Obligate heterozygotes in the families described in this report showed some manifestations 
of the disorder. Although intelligence in the heterozygotes was not impaired, some had 
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head circumferences on -2 SD Female II-3 (N40) was bom with an atrial septum defect, 
which is considered a manifestation of her carrier state 
Although the three families have clinical features in common, family N40 shows a 
markedly more severe phenotype comprising severe congenital heart defects in all four 
affected and profound mental retardation. In the latter family the C-terminal end of the 
predicted truncated protein is entirely different from that of the mutant proteins in N45 and 
N9 Kalscheuer et al ,4 suggested that the much shorter truncated mutant PQBP1 protein in 
N40 (164 amino acids, aa) as compared to N45 (194 aa) and N9 (192 aa), may give rise to 
aberrant protein-protein interactions The authors found that in lymphoblastoid cell lines of 
affected individuals from all four families (N45, N9, N40 and SHS), the concentration of 
PQBPl transcripts was markedly reduced with almost undetectable expression in family 
N40, probably reflecting nonsense-mediated mRNA decay. The difference in predicted 
protein and expression levels of the transcripts, might account for the more severe clinical 
phenotype in N40 in relation to the other families. 
The duplication observed in family N9 and the deletion found in N45 give rise to almost the 
same frameshift ". Both mutations have been observed in other XLMR families, 
respectively SHS and MRX55 4. In the SHS spastic paraplegia and small testes is observed 
in respectively 6 and 4 out of 8 affected males These features were not present in the 
affected males reported in this article Similarities observed in the families, include 
microcephaly, lean body habitus, long narrow faces with maxilla hypoplasia, prognathism 
and high arched palate. Moreover, the anal atresia seen in case 2 (N45) was also present in 
one patient with SHS In another SHS patient anal stenosis had been noted This anal 
abnormality can also be observed in another X-linked disorder, FG syndrome However, in 
the latter syndrome different facial characteristics and, additionally, hypotonia at young age 
and constipation is observed. 
In MRX55 the same deletion as in N45 has been detected 4.The three male patients of this 
family are moderately mentally retarded and one patient had small body size (height was 
159 cm, -3.5 SD). No other clinical signs have been reported, but the photograph of the 
index patient in the original report, shows a long and narrow face However, a normal head 
circumference of this individual (57 cm, -0.5 SD) was reported '4. 
It has recently been shown that the family with Renpennmg syndrome described by 
Renpenning et al., '7 and Stevenson et al,22 and of whom it was suggested to be allelic to 
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SHS, is indeed caused by mutations in the PQBP1 gene In addition, in the latter 
publication another family is reported with mental retardation and microcephaly in which 
also a defect in this gene was identified. Features common among affected males from the 
original Renpenning family are microcephaly, short stature and small testes One patient 
was diagnosed with bilateral ins coloboma 
In the original Renpenning family, the PQBP1 mutation is an insertion in exon 5 
(c.641insC) leading to a truncated protein and a premature stop codon at amino acid 
position 226. In the other family a novel AG dinucleotide deletion in exon 4 
(c.575_576delAG) leading to truncation and a premature stop codon at amino acid position 
198 was found Both mutations are further downstream in the gene than the previous 
reported mutations and leave the polar amino acid-rich PRD domain that is thought to bind 
to the transcription factor Brain-2 (Bm-2), intact. Since there is considerable overlap 
between clinical features in the patients of Renpenning syndrome, SHS and the three 
families reported here, it is interesting to know if there is an aberrant co-expression of the 
mutant proteins and Bm-2 in the two families reported by Lenski et α/.,23 as it had been 
suggested for the mutant proteins caused by the exon 4 mutations reported by Kalscheuere/ 
al. 4. Additionally, all mutations identified so far in the PQBPJ gene, lead to the 
disturbance or deletion of the C2 domain in the protein. A loss of functional C2 domain 
might therefore contribute to the pathogenesis of MRX(S) in all the families 
The degree of mental retardation differed intra- as well as interfamilial. In SHS, IQ range 
was mild in 1 patient and moderate in 4 patients In 3 of 5 patients from N9 and N45 IQ 
range was moderate as well, the other two individuals from N9 and N45 had an IQ 
corresponding to severe mental retardation In N40 the degree of MR was profound in all 
cases In the original Renpenning family, 18 of the 19 patients were diagnosed with severe 
MR However, in one affected individual with Renpenning syndrome and in two 
individuals with SHS, there was cognitive impairment, but IQ was in the borderline range. 
For only one patient within our families, the OFC was known at birth (case 6). He appeared 
to be microcephalic (-2 SD) which further declined at the age of 18 months (-4 SD). 
The adult heights of the affected males in the present study cluster below or at the lower 
end of the normal range Including the data from Stevenson et al. 22, in total 16 out of 26 
affected males have short stature, so this is indeed another characteristic of patients with 
PQBP1 mutations It was suggested that in SHS the associated growth retardation probably 
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begins during intrauterine life (IUGR) '6. Cases 4,5, 7 and 8 of our families were bom with 
birth weights < 3rd centile, the other cases and the affected males with SHS have birth 
weights that cluster around the 10lh and 25th centiles. 
Fichera et al.,24 reported on a family linked to Xpl 1.2 with 5 mentally retarded males with 
microcepahly spastic diplegia and characteristic facial features, and suggested it to be 
allelic to SHS. Moreover, lean habitus, high palate and nasal speech are features seen in 
patients reported with Lujan-Fryns syndrome (MIM_309520) and also in the patients 
described here. Therefore, it would be very interesting to know if mutations in the PQBPl 
gene indeed are the cause of the XLMR in these families. 
PQBPl has been implicated in a variety of neurodegenerative disorders due to its direct 
interaction with huntingtin, ataxin and other relevant polyglutamine containing proteins "," 
21. In none of the affected males however, the condition showed a progressive or 
neurodegenerative course. Clinical follow-up will show whether neurological deterioration 
at older age is a longterm feature of this syndrome or not. 
Our observations and previous reports indicate that patients with PQBPl mutations have a 
recognizable phenotype comprising mental retadation, microcephaly, short stature and lean 
habitus, post-adolescent facial characteristics, small testes and midline defects. Therefore 
mutation analysis of the PQBPl gene is warranted for mentally retarded patients with this 
phenotype, especially when family data are compatible with X-linked inheritance. 
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4.3 Clinical studies in the cerebral creatine deficiency 
syndrome caused by SLC6A8 mutations: broadening 
the adult phenotype 
Τ Kleefstra, J Muecke, EH Rosenberg, GS Salomons, A Tzschach, Η van Bokhoven, BBA 
de Vries, BCJ Hamel 
Abstract 
Recently, a novel X-linked mental retardation syndrome was identified caused by cerebral 
creatine deficiency, due to a mutation in the SLC6A8 gene that encodes for a creatine 
transporter Most patients have been identified by the marked reduction or absence of 
creatine on proton magnetic resonance spectroscopy (Η-MRS) at young age and had mental 
retardation, severe expressive speech and language difficulties and seizures 
Here the phenotypic characteristics of three additional male patients and two female 
carriers (2 unrelated families) are reported, including two patients at older age These 
patients showed in addition to the mental retardation and the dysphasia, myopathic facies, 
ptosis, soft skin, hyperextensible joints, gastro-intestinal problems and severe mood 
disorder 
Based on these findings, the clinical presentation of creatine transporter deficiency is 
broader than initial appreciated and it might include progression of intestinal, neurological 




X-linked mental retardation (XLMR) is a heterogeneous group of entities that accounts for 
10-12% of all mental retardation ' · 2 . XLMR conditions can be classified as either 
syndromal (MRXS) or non-syndromal (MRX), depending on the presence or absence of 
specific distinguishing clinical, morphological, neurological or metabolic anomalies. At 
present more than 30 genes have been identified that play a role in MRXS, whereas for 
MRX, 20 causative genes are known 2. Observations in the last few years have shown that 
an increasing number of genes play a role in both syndromic and in non-syndromic forms 
of XLMR 3'4, suggesting allelism for MRX and MRXS. Therefore, careful clinical (re-) 
examination of patients with mutations in identified XLMR genes, is important to establish 
the phenotypic spectrum. 
Recently, a novel XLMR syndrome was identified, caused by creatine deficiency in the 
brain due to mutations in the creatine transporter gene SLC6A8 5'6. So far, 15 patients from 
8 families with a mutation in SLC6A8, have been reported and symptoms were mainly 
confined to neurological and metabolic findings 5"12. The phenotype comprised mental 
retardation, low weight, autistic behaviour, epilepsy and expressive speech and language 
delay. Additional investigations have shown impaired uptake of creatine in fibroblasts, 
increased levels of creatinexreatinine ratio in urine and a marked reduction of creatine 
signal in the Η-MRS of brain . 
Recently, the prevalence of mutations in SLC6A8 in a cohort of 290 unrelated (X-linked) 
families was estimated to be at least 2.1%, as 6 pathogenic sequence changes were found '3. 
To broaden the insight into the phenotypic spectrum of patients with a defect in the creatine 
metabolism, clinical features in 3 affected male patients and 2 females being heterozygous 
for the pathogenic mutation from 2 unrelated families were evaluated and compared to the 
already known clinical hallmarks resulting from SLC6A8 mutations. 
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Subjects and Methods 
Families 
The two families (family N87 and Dil) (figure 1) had been ascertained, when they were 
referred for genetic counselling because of the presence of more than one retarded male in 
the family Informed consent was obtained for both families DNA of 3 members of family 
N87 and 4 members of Dl 1 respectively, was collected and stored (www euromrx com) 
Urine samples were recently obtained of the two affected males, their sister and her son of 
family N87 and both urine and fibroblasts of the affected male and his mother of family 
DM 
In both families, pathogenic mutations in the creatine transporter had been identified 
previously ' 
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Figure 1 Pedigrees of family N87 (left) and Dl 1 (right) 
Metabolic studies 
Metabo! ^ studies included creatine creatinine measurements in urine and creatine uptake 





Family 1 (N87) 
Case 1 was the oldest son bom to healthy non-consanguineous parents. Data on early 
history were lacking. From young age, his mental development was delayed, he was not 
able to write or read. He worked in a sheltered environment until age of 57 years when he 
was institutionalized. His physical health was unremarkable. 
On examination at the age of 68 years, height was 164 cm (<-2.5 SD), weight 51 kg (-1 SD) 
and head circumference 57 cm (-1/0 SD). He had an asymmetric face, bilateral ptosis, broad 
nasal tip and short philtrum, thoracic kyphosis, scoliosis and hanging shoulders (figure 2A-
C). His abdomen was distended and his nails showed onychomycosis. He spoke with short 
sentences. 
Case 2 was the younger brother of patient 1. No history on early life events were known. 
During childhood he attended special education and learned to write and read. As an adult, 
he worked in a sheltered environment. After the death of his father (when patient was 43 
years of age), severe regression in cognitive and social functions occured, believed to be the 
result of chronic mood disturbance. Since the age of 52 years he became institutionalized 
and continued to have depressions. In his fifties, he had urological problems 
(urethrastenosis) and gastrointestinal problems (chronic constipation and a bowel ileus). 
Spontaneous luxations of several digits had occured since the age of 50 years. Photo's of 
the brotherpair at younger age, of case 2 at the age of 57 years and the age of 60 years, 
clearly show the progressiveness in the clinical features in this patient (figures 2A, 3A-D). 
The patient had a height of 167 cm (-2.5 SD), weight of 64 kg (0 SD) and head 
circumference of 59.5 cm (0/+1 SD). At the age of 64 years, he had a myopathic facies 
with full eyebrows, downslanted palpebral fissures, mild midfacial hypoplasia and full lips, 
hanging shoulders, thoracic kyphosis, normal genitals, simian creases, soft and lax skin and 
deviated digits (status after luxations). He was emotionally unstable and had no speech. 
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Figure 2A: brotherpair of family N87 at Figure 3, A and Β: Case 2 at the age of 57 years 
younger ages. Case 1 on the righi. Case 2 on and C and D, at the age of 64 years. Note the 
the left. 2B and C: Case 1 at the age of 68 progressiveness in facial features, 
years. Note ptosis. 
The sister was 59 years old and was carrier of the p.Cys337Tryp mutation. She had 
learning difficulties (finished primary school only). Since the age of 55, she had severe 
constipation requiring surgical intervention. 
Family! (Dil) 
Case 3 was bom after an uneventful pregnancy and delivery with a birth weight of 3000g, 
length of 47.5 cm and a head circumference of 33 cm. His maternal uncle, two brothers and 
one sister of his maternal grandmother were mentally retarded with unknown cause. 
Because of the familial mental retardation, developmental delay was diagnosed early in this 
patient. Additionally, severe expressive language problems were reported At the age of 7 
years, he had a height of 114 cm (-2.5 SD) and a head circumference of 49.2 cm (-2 SD). 
No characteristic facial features were seen (figure 5). He had severe mental retardation, but 
no seizures. 
The mother was 33 years of age. She was described as a very simply minded woman 
without profession, but without mental retardation or facial minor malformations. She had a 
short stature but no objective height measurements were known. 
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Table 1 : Summary of clinical symptoms in patients with SLC6A8 mutations 
Features 
General 
Number of patients 
(per family) 
Age at examination (years) 
Neurological 
Degree menial retardation 






















Increased urine creatine:creatinine ratio 
Impaired creatine uptake fibroblasts 
Absence/reduced creatine on H-MRS 


























































































































































NA Not applicable 
*This patient has also been described in the reports of Salomons et al, 2001 and DeGrauw et al., 2003 
**Only present in the affected older males of this family 
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No further data were available on the other affected family members. 
Figure 5: Case 3 at the age of 7 years. Normal facial characteristics. 
Molecular and metabolic studies 
The molecular and metabolic findings of the patients and the carrier female of family 1 
(N87) have been reported previously lj. These included the identification of a missense 
mutation of a highly conserved residu (c.lOllC—»G; p.C337W) and increased 
creatinexreatinine ratio's in urine samples of both affected brothers (1.11 and 1.65, normal 
<0.24) l4 and this ratio in urine of the sister was just above normal (0.27; n<0.24). Her son 
had normal creatinexreatinine levels in the urine but was not available for further studies. 
In family 2 (DU) a C.1661C—»T change was detected that resulted in a substitution of a 
conserved amino acid as well (p.P554L). In addition to the molecular findings that were 
reported previously ' , an increased creatinexreatinine ratio in an urine sample of case 3 
(2.3; n=<0.24) was identified. In the mother, being heterozygous for the p.P544L mutation, 
a slightly elevated creatinexreatinine ratio in urine was found (0.28; n<0.24). Impaired 
uptake of creatine in fibroblasts was detected in case 3, but not in fibroblasts of his mother. 
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Discussion 
In this report, the clinical features of 3 patients and two obligate female carriers with 
mutations in the SLC6A8 gene are described. In contrast to previous reports that 
concentrated mainly on metabolic and neurologic features in younger patients, here two 
elderly affected males are included with mutations in the SLC6A8 gene contributing to the 
phenotypic spectrum of this new creatine deficiency syndrome. 
The identification of the first patient with a creatine transport and the two other inborn 
errors of creatine metabolism, the creatine biosynthesis errors, arginine:glycine 
amidinotransferase (AGAT) deficiency [MIM 602360] and guanidinoacetate 
methyltransferase (GAMT) deficiency [MIM 601240] share the almost complete lack of 
creatine signal in the brain, as measured by in vivo Η-MRS 5 · 1 5 " 1 8 . Clinical features 
characteristic for all creatine deficiency syndromes are mental retardation, expressive 
speech and language delay and often epilepsy. In addition, in SLC6A8 and GAMT-
deficient patients autistic features are seen and in the latter, extrapyramidal signs might be 
present as well '2 ' '9. Metabolite measurements in plasma fluids are indicative of the specific 
disorders; creatinercreatinine ratio is increased in urine of SLC6A8 deficient males, 
whereas guanidinoacetate is increased in urine and plasma of GAMT-deficient patients, and 
creatine and guanidinoacetate is likely reduced in these body fluids of AGAT deficient 
patients. 
In table 1, a summary of the clinical features in our patients and previously reported cases is 
shown. A difference in clinical features between the adult patients and patients at childhood 
age can be observed. Features present in the adult patients are, myopathic facies (including 
ptosis), hyperextensible joints, soft skin and gastro-intestinal problems as megacolon, 
severe constipation and bowel ileus. There might be several reasons for this difference in 
clinical presentation. It is possible that there is a selection bias in the identified younger 
patients. With the exception of the two families of Mancini et al., " all younger patients 
underwent Η-MRS of brain as part of a diagnostic workup because of encephalopathy, 
speech problems and seizures and all were diagnosed by absence of creatine on this 
spectroscopy. The currently reported older patients were identified through candidate gene 
analysis and by screening of the SLC6A8 gene in a XLMR cohort, without knowledge of 
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phenotypic characteristics. In addition clinical examination was not performed extensively 
in all previously reported patients, which might lead to under recognition of several 
symptoms. Another likely explanation is that the condition is progressive and gives rise to 
other features at later age. It is of note that in two brothers progressive atrophy of the brain 
was seen by image studies 8. Therefore, clinical follow-up should give more insight into the 
phenotypic outcome at later age. 
The two female carriers presented here do have learning difficulties, which is in line with 
previous reports l2, although no objective cognitive parameters are known in either of the 
two. The female carrier of family 1 experienced the same severe bowel problems as her 
brother, which might well reflect a symptom of creatine transporter deficiency. 
The family reported by Hahn et al., '0 and the 3 patients reported here, show additional 
phenotypic characteristics including gastrointestinal problems in at least 4 affected males 
and broaden the phenotypic spectrum of SLC6A8 deficiency. Therefore, the phenotypic 
hallmarks of this XLMR syndrome not only comprise mental retardation, seizures, 
expressive speech and language problems, but may also include hypotonia, short stature, 
myopathic facies including ptosis, soft skin and gastro-intestinal problems. These clinical 
signs in mentally retarded (elder) males, might indicate creatine deficiency, particularly 
when the pedigree implicates X-linked inheritance. In younger males, hypotonia, short 
stature or low weight, height on the borderline of normal range and mild movement 
disorder appear the most prominent signs. Measurement of creatinexreatinine ratio in urine, 
is a relatively simple first step to search for this creatine transporter deficiency syndrome. 
In case of increased creatinexreatinine, mutational analysis and a creatine uptake study can 
confirm the defect on molecular and functional level. 
In conclusion, the clinical presentation of SLC6A8 deficiency is broader than initial 
appreciated and it might include progression of intestinal, neurological and psychiatric 
problems later in adult life. 
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Bridging to the autosomal mental retardation genes 
1 Disruption of the gene Euchromatin Histone Methyl Transferase! (Eu-HMTasel) 
is associated with the 9q34 subtelomeric deletion syndrome 
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5.1 Disruption of the gene Euchromatin Historie Methyl 
Transferase! (Eu-HMTasel) is associated with the 9q34 
subtelomeric deletion syndrome 
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Nillesen, EA Sistermans, BCJ Hamel, D de Bruijn, J-P Fryns, HG Yntema, HG Brunner, 
BBA de Vries, H van Bokhoven 
J Med Genet 2005 24 299-306 
Abstract 
A new syndrome has recently been recognised by the thorough analysis of patients with a 
terminal submicroscopic subtelomeric deletion of chromosome 9q These patients have in 
common severe mental retardation, hypotonia, brachycephaly, flat face with hypertelorism, 
synophrys, anteverted nares, thickened lower lip, carp mouth with macroglossia and 
conotruncal heart defects The minimal critical region responsible for this 9q subtelomenc 
deletion syndrome (9q-), is approximately 1 2 Mb and encompasses at least 14 genes 
Here we have characterised the breakpoints of a de novo balanced translocation 
t(X,9)(pl 1 23,q34 3) in a mentally retarded female patient with clinical features similar to 
the 9q- syndrome Sequence analysis of the breakpoints revealed that the translocation is 
fully balanced and that only one gene on chromosome 9 was disrupted Euchromatin 
Histone Methyl Transferase! (Eu-HMTasel), encoding a histone H3 lysine 9 
methyltransferase (H3-K9 HMTase) This result strongly indicates that haploinsufficiency 
of Eu-HMTasel is responsible for the 9q submicroscopic subtelomenc deletion syndrome 
This observation is further supported by the spatio-temporal expression of the gene Using 
tissue In Situ Hybridization (ISH) studies in mouse embryos and adult brain, we showed 
that Eu-HMTasel is expressed in the developing nervous system and in specific peripheral 
tissues While the expression in brain is selectively downregulated in the adult brain, 
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substantial expression is retained in the olfactory bulb, anterior/ventral lateral ventricular 
wall, the hippocampus and weak in the piriform cortex. This expression pattern suggests a 
role in the CNS development and function, which is in line with the severe mental 
retardation and behaviour problems in patients who lack one copy of the gene. 
Introduction 
Submicroscopic telomeric deletions account for about 5% of the patients with unexplained 
mental retardation '"3 .This figure is dependent on the patient selection used for studying 
such aberrations and ranges from 0.5% in mild mental retardation to 7.4% in childen with 
moderate-severe mental retardation 4. Some submicroscopic telomeric deletions are 
associated with a specific phenotype, such as lp-, 4p-, 5p-, 9p-, 18p- and 17p-2'3. For most 
subtelomeric deletions a specific phenotype has not yet been defined, mainly because of the 
paucity of reported cases. The 9q34.3 deletion emerges as one of the more common 
telomeric deletions whose phenotype becomes gradually better defined. Untili now, 22 
patients have been reported with a submicroscopic subtelomeric deletion of 9q "". The 
phenotypic features commonly seen in these patients are severe mental retardation, 
hypotonia, microcephaly, flat face with hypertelorism, synophrys, short nose with 
anteverted nares, thickened lower lip and carp mouth with tongue protrusion and 
conotruncal heart defects. Less frequently observed features are obesity, hearing loss, 
urogenital abnormalities and behavioural problems. Stewart et al.u defined the critical 
chromosomal region responsible for this phenotype by mapping the deletion endpoints in 
12 patients with a subtelomeric deletion of chromosome 9qter. This minimal critical region 
is approximate 1.2 megabase (Mb) encompassing at least 14 genes or transcripts and 
suggested that haploinsufficiency of one or more genes within this region, most likely 
accounts for the 9q- syndrome. 
We have previously reported the characterization of the breakpoints of a de novo balanced 
translocation t(X;9)(pl 1.23;q34.3) present in a severely mentally retarded female patient '2. 
The translocation was found to be completely balanced on the DNA level and disrupted on 
the X-chromosome the ZNF81 gene, while on chromosome 9 the breakpoint disrupted the 
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Eu-HMTasel gene. The ZNF81 gene was subsequently screened for mutations in a cohort 
of over 300 male patients with X-linked mental retardation. A missense mutation in the 
ZNF81 gene was identified in a linked family with mild non-specific mental retardation '". 
However, the non-syndromic phenotype in this family is clearly different from that of the 
translocation patient, indicating that the disruption of ZNF81 is not causitive for the severe 
clinical features in this patient. Here, we have performed a careful evaluation of the clinical 
presentation of the t(X;9) patient, which revealed a striking phenotypic overlap with the 9q-
syndrome. Interestingly, the chromosome 9 breakpoint in this patient disrupts the Eu-
HMTasel gene, which precisely maps to the common deletion region found in the 9q-
syndrome. The specific disruption of Eu-HMTasel suggest that haploinsufficiency of this 
gene is responsible for the larger part of the 9q- phenotype. 
Subjects and Methods 
Subjects 
Patient 
The index patient had been referred to our department for genetic diagnosis. Routine 
cytogenetic studies revealed a karyotype that showed a translocation t(X;9)(pl 1.2;q34.3). 
This translocation appeared to be de novo because both parents had a normal karyotype. 
Patient panel 
A selection of 37 mentally retarded patients with normal karyotype but with facial features 
seen in the 9q- syndrome and previously screened routinely for submicroscopic telomeric 
deletions within our department, was prepared to search for aberrations. Genomic DNA of 
each patient was isolated according to standard procedures '3. 
Multiplex Ligation Dependent Probe Amplification (MLPA) 
A specifically designed set of probes for testing for subtelomeric chromosomal imbalances, 
SALSA P036 Human Telomere Test Kit (MRC-Holland, Amsterdam, the Netherlands), 
was used for subtelomere screening '4 and included one probe in the MRPL41 gene at 9q34. 
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In addition, a specifically designed probe set including synthetic probes for the 9q 
subtelomeric region was developed. Probe preparation has been described previously (see 
electronic datatabase information). The MLPA mix contained 2 probes for CACNAIB and 
2 probes for Eu-HMTasel. The full sequences of these probes are available upon request. 
MLPA analysis was performed for all 37 selected patients by using standard kits and was 
carried out as described by Schouten et a/.15 with minor modifications. Briefly, 200-400 ng 
DNA was diluted with milliQ to 8 μΐ and heated at 980C for 5 min (GeneAmp PCR System 
9700, Applied Biosystems, Foster City, CA, USA). The probe mix (1.5 μΐ per sample) was 
mixed 1:1 with a salt solution (1.5 M KCl, 300 mM Tris-HCl pH 8.5, 1 mM EDTA) and 
samples were heated for 1 min at 950C and incubated overnight at 60oC. Next the Ligation-
65 mix (MRC Holland) was added and incubated for 15 min at 540C. By heating at 980C 
for 1 min Ligase-65 was inactivated. The ligation products were amplified by PCR using 
the common primer set with the 6-FAM label distributed by the supplier. Amplification 
products were identified and quantified by capillary electrophoresis on an ABI 3100 genetic 
analyzer, using Genescan Analysis Software (version 3.7) and Genotyper software, all from 
Applied Biosystems, Foster City, CA, USA. When synthetic probes were used, they were 
first diluted to a concentration of ΙμΜ. A synthetic probe mix was made of Ιμΐ of each 
diluted primer and the end-volume was adjusted to 250μ1 with TE. For each reaction, 0.5μ1 
of this mix was added to 1.5μ1 of the SALSA P036 kit and reactions were performed as 
described above. 
Mutation screening 
The entire coding region of the Eu-HMTasel gene was sequenced in 15 of the 37 selected 
patients using genomic DNA as a template. Primers were designed to amplify all the 25 
exons of the gene as well as 5 alternative exons in splice variants. Primer sequences and 
PCR conditions are available upon request. PCR products were directly sequenced, after 
purification with a Qiagen PCR purification kit, on an Applied Biosystems 3730 automated 
sequencer using the same primers as in the PCR. 
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Expression studies 
Mouse Eu-HMTasel expression pattern 
With the expressed sequence tag (EST) information contained in the NCBI unigene 
database, an (in silico) expression pattern of the Eu-HMTasel gene was generated All 
ESTs in the Eu-HMTasel unigene cluster (Mm 24176), and their associated dbEST library 
IDs (LIDs) were re-clustered according to the tissues from which the libraries originated A 
listing of the tissues used for all EST libraries was collected from the NCBI Unified Library 
Database (UNILIB) 
Tissue In Situ Hybridization (ISH) 
A 834 bp probe was developed by selecting a primer pair with T3 and T7 stretches (5'-
taaccctcactaaagggagatgtcctaatgttcagtaatgg-3' and 5'- taatacgactcactatagggccaagtgtcggcact 
caagc -3') that allowed the specific amplification of the 3'UTR of the mouse orthologue of 
Eu-HMTasel Sense and antisense labeled cDNA probes were developed by using T7 and 
T3 RNA polymerase, respectively The ISH was performed according to the procedures 
described by Smidt et al ,'6 on embryos of stage E14 5 and E16 5 and on adult brain to 
evaluate the expression pattern 
Results 
9q- phenotype in a patient with a t(X;9)(pll.2;q34.3) 
The propositus is a Caucasian girl bom after 37 weeks gestation, with a birth weight of 3100 
grams (25lh centile) and a birth length of 49 cm (25lh centile) Pregnancy and delivery were 
uneventful She is the second daughter of healthy, non-consanguineous parents In the 
neonatal period hypotonia and feeding problems were present The anterior fontanel was 
enlarged and closed at the age of 2 years 
At the age of 2 years, an Atrial Septum Defect type II with a pulmonary stenosis was 
diagnosed without hemodynamic consequence 
129 
Chapter 5 
Psychomotor development was delayed, she walked at the age of 2 years and 6 months, 
with hardly any speech development. She has a mild-moderate conductive hearing loss on 
both sides. At the age of 4 years, she had epileptic seizures with EEG abnormalities, but 
thereafter no more seizures occurred and EEG patterns returned to normal. She had severe 
behavioural problems involving autistic features, aggressiveness and auto-mutilation. 
Menarche occured at 10 years of age. When we examined her at the age of 11 years, she 
was a non-cooperative, mildly obese girl with apparently normal height and head 
circumference, brachycephalic skull and facial dysmorphisms: synophrys, upsianting of the 
palpebral fissures, hypertelorism, midface hypoplasia, broad nasal bridge, anteverted nares, 
protrusion of the tongue, thickened lower lip, pointed chin and small ears (figure 1). 
In table 1 a summary of clinical features in 22 previously reported patients with 
subtelomeric 9q34.3 deletions is shown 7 ; 9 ; ". Stewart et α/.," recently analysed the clinical 
and molecular characteristics of 17 of these patients. Comparing the characteristics 
observed in the index patient with the clinical features of the other reported patients, the 
overlap is striking (table 1). Features commonly seen and present in the index patient are: 
severe mental retardation, hypotonia, brachycephaly, mid facial hypoplasia with synophrys 
and/or arched eyebrows, anteverted nares, carp shape mouth, thick lower lip, tongue 
protrusion and heart defects. In addition, behavioural problems, sleep disturbances and 
seizures were present in the proband as well. 
Figure 1: The index patient with a 
disruption of Eu-HMTasel at age 11. Note 
brachycephaly, flattened face, 
upwardslanting of palpebral fissures, 
hypertelorism, synophrys, broad nasal 
bridge, anteverted nares, protrusion of the 
tongue, eversion of lower lip and pointed 
chin. 
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Eu-HMTasel is disrupted by the breakpoint at chromosome 9 
By previous studies, we sequenced the breakpoints of the translocation t(X;9)(pll.2;q34.3) 
and found that the coding sequences of ZNF81 and Eu-HMTasel respectively, were 
disrupted l 2. In figure 2 (A and B), a schematically drawing of the subtelomeric region of 
9q34.3 and the derivative chromosome 9 with the fusion of the disrupted genes ZNF81 and 
Eu-HMTasel is shown. Translocations have been reported previously in 9q- syndrome 
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Figure 2: Schematic view of the subtelomeric region of 9q34.3, including the minimal critical region of 1.2 Mb 
(A), the derivative chromosome 9 (B) and the Eu-HMTasel protein (C). A: Positions and orientation of the genes 
MRPL41, Eu-HMTasel and CACNAIB in the minimal 1.2 Mb critical interval. Vertical arrow heads indicate the 
positions of the probes used in the MLPA. B: Schematic diagram (not to scale) indicating the exon-intron 
structures ofZNFSl and Eu-HMTasel relative to the breakpoint region. The breakpoint in Eu-HMTasel is situated 
11 bp from the 3' end of exon 8 resulting in a derivative chromosome 9 with a fusion of the 5'end of the gene Eu-
HMTasel to the 5'end of the X-chromosomal gene ZNF81 . The translocation was found to be fully balanced on 
the genomic level. C: The positions of the 4 novel identified polymorphisms in the protein is shown. Note the 
S809C and D229N which are present in the conserved ankyrin repeats but also identified in one of the two parents 
of the respective patients. 
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Figure 3: Expression pallem of Eu-HMTasel 
estimated by in silico analysis. The in silico 
Eu-HMTasel expression pattern in selected 
mouse tissues generated from EST data in 
unigene cluster Mm.24176. Expression levels 
are indicated as numbers of EST sequences 
per 50000 total ESTs in each tissue. 
However, sequence analysis of both the X-chromosomal and chromosome 9 breakpoints 
revealed that the translocation described here, is fully balanced on the genomic level (data 
not shown). From the der(9) chromosome, a chimaeric transcript is produced consisting of 
part of the ZNF8I gene and an Alu-repeat sequence derived from chromosome 9. This Alu-
repeat is in the reverse orientation as compared to the Eu-HMTasel gene and therefore has 
the property to inhibit the expression of the normal Eu-HMTasel gene by mechanisms such 
as RNAi17. To investigate this, we performed RT-PCR on the Eu-HMTasel gene in 
lymphoblasts of the proband, but a transcript could still be detected (data not shown). 
The finding of a disturbed Eu-HMTasel in the translocation patient and the large clinical 
overlap of the phenotype of this patient and patients with subtelomeric 9q deletions as 
shown in table 1, strongly indicates that haploinsufficiency of Eu-HMTasel is likely to be 
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Figure 4: Eu-HMTasel 1SH on saggital sections of a mouse embryo of stage E14.5. A: Overview of a lateral and 
medial section through the embryo. B: Lateral section showing expression in the developing retina (Ret). C: More 
medial section showing expression in the lateral part of the forebrain area (CNS). D: More medial view on the 
developing head. Expression was indicated in the olfactory epithelium (OF), the dorsal surface of the tongue, as 
the lonque itself (dT) and again the developing nervous system (CNS). E: Developing body structures. Expression 
was clearly found in the lung and kidney. F: Expression in the dorsal root ganglia (DRG) and again the CNS. 
Figure 5: Eu-HMTasel ISH on saggital sections of a mouse embryo of stage E16.5 A) Overview of a lateral and 
medial section through the embryo. The expression in the thymus and spinal cord (SpC) is indicated. B) Lateral 
section of the embryo head showing expression in the retina and CNS. C) Expression in the regions of the CNS 
including the developing hippocampus (Hip), also note the layer formation of the developing cortex. D) 
Expression in the developing whiskers and CNS. E) Expression in the Lung, dorsal root ganglia (DRG), Gut and 
Kidney. 
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shown responsible for the majority of symptoms. 
Tissue In Situ Hybridization (ISH) 
Counting the numbers oi Eu-HMTasel derived transcripts in the unigene database revealed 
that Eu-HMTasel is expressed throughout embryonic development, starting as early as in 
the fertilized oocyte (figure 3). High relative expression was also observed in cDNA 
libraries obtained from neonatal and adult brain, eye, germ cells and adult cardiac muscle. 
In order to obtain a more accurate impression of the spatio-temporal expression of Eu-
HMTasel during development, we dessigned a probe suitable for tissue In Situ 
Hybridization (ISH). This analysis revealed that Eu-HMTasel is expressed in a broad array 
of structures in the developing mouse (figures 4 and 5). At these stages Eu-HMTasel is 
expressed in all structures of the central nervous system (CNS). Interestingly, the 
developing cortex shows a laminar structure at E 16.5 indicating that regulation of this gene 
occurs in the specific layers. The embryonic expression pattern is restricted in the adult 
brain to the olfactory bulb, the anterior/ventral ventricular wall, the hippocampus and 
piriform cortex (figure 6). 
Figure 6: ISH on coronal sections of adult mouse brain from rostral to caudal (bregma 3.5 to -3.5) using a DIG-
labeled RNA probe specific for Eu-HMTasel . In rostral sections expression was detected in the olfactory bulb 
(OB) and the ventral ventricle wall (LV). More caudal expression was detected in different areas of the 
hippocampus (CAI, CA2, CA3, DG (dentate gyrus)) and weak in the piriform cortex (Pir) The position of the 









Outside the CNS several tissues express Eu-HMTasel (figures 4 and 5), including the 
developing nasal epithelium, tongue, thymus, gut, lungs and kidney. 
MLPA analysis and mutation screening 
Haploinsufficiency for the Eu-HMTasel gene in the index patient and in patients with a 
9qter deletion causes a strikingly similar phenotype. Therefore, it is likely that 
microdeletions or other inactivating mutations in the Eu-HMTael gene may account for 
other patients with a similar phenotype but without a demonstratable microscopic deletion. 
To investigate this, we selected 37 patients with a comparitive phenotype for MLPA studies 
on subtelomeric submicroscopic 9q deletions and subsequently, mutation analysis of the 
Eu-HMTasel gene in 15 of them. MLPA probes were selected for the Eu-HMTasel gene 
and flanking genes MRPL41 and CACNA1B (figure 2A). While MLPA analysis provided 
clear evidence for monosomy of chromosome 9qter in a previously reported deletion 
patient 5, the selected pobes failed to detect any new deletions in the 37 patients that we 
selected (data not shown). Direct sequence analysis of the Eu-HMTasel gene in 15 of these 
patients, identified eight sequence variants that were predicted to result in amino acid (aa) 
substitutions in the Eu-HMTasel protein (figure 2C). Four of these were already known in 
SNP databases and are likely polymorphisms (table 2). Segregation studies of the other 4 
changes, revealed that each of the changes was present in one of the phenotypically normal 
parents, indicating that these represent polymorphisms as well. 







































Father and mother heterozygote 
Father heterozygote 
Mother heterozygote 
*NA = Not Applicable 
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Discussion 
We here describe that a patient with a disruption of Eu-HMTasel, has the same clinical 
characteristics that are seen in patients with a submicroscopic subtelomeric 9q deletion (9q-
) This strongly indicates that haploinsufficiency of Eu-HMTasel is responsible for the 
phenotype in this patient as well as for the major part of the 9q- syndrome Further support 
for this is provided by a parallel paper in which two patients are reported with a 9q-
phenotype and microdeletions that define the critical region encompassing two genes 
including Eu-HMTasel '8 Our results provided a rationale for mutation screening in 
patients with a similar phenotype We performed MLPA in 37 patients sharing some of the 
clinical features and sequenced the entire coding region in 15 ot them In none of these 
patients Eu-HMTasel abnormalities were detected However, this does not imply that such 
patients do not exist The numbers tested here may have been too low to identify additional 
mutations and patients with a phenotype similar to that seen in individuals with 9q-
syndrome but without chromosomal abnormalities are scarce To increase the chances to 
identify such deletions, we have included the reported Eu-HMTasel probes in the standard 
MLPA kit that is used for the detection of subtelomeric deletions in mentally retarded 
patients in our DNA-Diagnostic services 
The phenotypic overlap between the patient with the disrupted Eu-HMTasel gene and the 
9q- syndrome is striking (figure 1, table 1 ) All of the major features of the 9q- syndrome 
were present in the translocation patient as well as some less reported features behavioural 
problems, sleep disturbances and seizures The only significant exception is microcephaly, 
which is common in 9q- patients (18 of 22 cases), but absent in the translocation patient 
This may just be a reflection of the clinical variability that characterizes 9q- syndrome 
patients Another likely explanation is that the microcephaly in 9q- syndrome patients is not 
caused by haploinsufficiency for the Eu-HMTasel gene, but due to deletion of another gene 
from the subtelomeric region of chromosome 9q This explanation may also apply to some 
of the other, less frequent, clinical features such as soft brittle hair with partial alopecia and 
urine tract anomalies 
Eu-HMTasel is abundantly expressed in embryonic stem cells, in brain- and eye during 
embryonic development, various adult brain tissues and adult cardiac muscle according to 
EST data extracted from electronic databases We have shown with ISH that Eu-HMTasel 
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is expressed in a broad array of structures in the developing mouse whereas in the adult 
mouse, the expression pattern is confined to a few regions of the brain. This expression 
pattern of the Eu-HMTasel supports the hypothesis that this gene is an excellent candidate 
to be the cause of mental retardation and congenital abnormalities. The expression in the 
adult brain is restricted to specific areas of the olfactory bulb, the anterior/ventral 
ventricular wall, the hippocampus and piriform cortex. Interestingly, these structures are all 
known to harbour cell populations with high proliferative potential '9"2'. As widespread 
expression of Eu-HMTasel is also observed in embryonic CNS development, it appears 
that this gene has an important role in proliferation of neuronal precursor cells in 
neurogenesis. Alternatively, the high expression of the gene in regions containing dividing 
cells may also point to a role of the Eu-HMTasel protein in mitotic silencing of neuronal 
precursor cells after cell division. For both of these postulated functions it is of interest that 
Eu-HMTasel acts as an epigenetic regulator of transcription. 
Eu-HMTasel was identified in 2002 2 2 and was found to be closely related to the G9a 
protein. Both Eu-HMTasel and G9a are H3-K.9 HMTases, which are present in 
euchromatic regions, that form complexes with heterochromatin protein 1 (ΗΡΙγ) and a 
subset of E2F transcription factors22. The E2F-6 complex preferentially occupies target 
promotors in Go cells rather than G ι cells, suggesting a role in silencing of target genes in 
quiescent cells. In view of the restricted expression in adult mouse brain it appears likely 
that Eu-HMTasel has an important role in carrying out the epigenetic histone modifications 
which are needed to transfer a subset of the neuronal precursor cells into the Go phase after 
cell division. It was shown recently that homozygous mutant mouse embryos with a 
mutation in G9a, die at 8.5 dpc, implicating that euchromatin H3-K.9 methylation is 
essential for early embryogenesis 2 3. Similar findings were found with ESET, another H3-
K9 HMTase 24. These authors reported that ESET null embryos exhibit peri-implantation 
lethality. In addition to histone methylation, H3-K.9 HMTases also influence DNA 
methylation25,26. Thus, G9a null embryo stem cells (ES) show altered DNA methylation in 
the Prader-Willi imprinted region 2 5. Knockout mice for Eu-HMTasel have not been 
reported to date. 
Studies in recent years have revealed that histone methylation plays an important role in 
modulating chromatin structure and function27'28. Histone methylation occurs on arginine 
and lysine residues at the N-terminal tails of histones H3 and H4 and is catalyzed by two 
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distinct protein families, the PRMTl and the SET-domain-containing family. Recently, a 
third family of histone methyl transferases (HMTases) that target lysine 79, located in the 
globular domain of histone H3, was reported29 .Thus far, six lysine residues located on 
histones H3 (lysines 4, 9, 27, 36 and 79) and H4 (lysine 20) have been reported to be sites 
of methylation. Lysine 9 methylation (H3-K9) is the best studied due to its fundamental 
role in chromatin formation, transcriptional silencing, X chromosome inactivation and 
DNA methylation 30 . 
There is a growing number of mental retardation genes that appear to play a role in 
chromatin remodelling: MECP2, RSK2, XNP, DNTM3B, CBP 3I. Three of these genes, 
MECP2, RSK2, XNP, are involved in syndromic and non-syndromic forms of X-linked 
mental retardation (XLMR). Mutations in the MECP2 gene cause RTT syndrome in 
females, mostly in isolated cases 3I'32. In addition, there are a number of families in which 
MECP2 mutations cause male-limited non-specific X-linked mental retardation3''4. The 
MeCP2 protein is a methyl-CpG-binding protein that forms transcription repression 
complexes with Sin3a and several histone deactelyses :n·35·36. The RSK2 gene is involved in 
Coffin-Lowry syndrome37 and in one family, non-specific mental retardation 3ii. The 
corresponding protein is a ribosomal S6 kinase involved in RAS-MAPK-ERK signalling. In 
addition, it has been shown that RSK2 can phosphorylate histone H3 and the CREB-
binding protein CBP, which in turn acetylates histone H3 3 9 ·4 0 . Mutations in the CBP gene 
are causative for Rubinstein-Taybi syndrome41. The XNP gene is the third X-chromosomal 
XLMR gene with a role in chromatin remodelling. Mutations in the XNP gene cause the 
ATRX syndrome and a number of other syndromes with overlapping clinical features 42. 
Also non-specific XLMR has been reported in two families 4 3 ·4 4 . XNP (X-linked nuclear 
protein) is a member of the Swi/Snf family of RNA helicases. Interaction between the XNP 
protein and two heterochromatin-binding proteins, HP1 and EZH2, is well documented 45. 
Interestingly, two recently identified XLMR genes encode also predicted interactors of 
HP1, the related and KRAB-ZNF (Krüppel associated box-zinc finger proteins) ZNF41 and 
ZNFSl'2,46. The current identification of Eu-HMTasel as the causative gene in yet another 
mental retardation syndrome strongly suggests that disruption of epigenetic patterns is a 
common cause of mental retardation and indicates that this type of transcriptional 




Accession numbers and URLs for data presented in this report are as follows 
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for Eu-HMTasel accession number NM_ Q9H9BI (human) 
and NM_BC056938 (mouse). 
MRC-Holland, http://www.mrc-holland.com/ (for SALSA P036 Human Telomere Test Kit) MLPA, 
http://www.mlpa.com/mlpa protocols.htm 
UCSC Genome Browser (Golden Path), http://eenome.ucsc.edu/cgi-bin/ (July 2003 and May 2004 Build) 
NCBI Unified Library Database (UNILIB), http://www.ncbi nlm mh.gov/UniGene/clust.cgi 
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6.1 Gene identification and brain function 
Since the 1970s the role of the X-chromosome in cognition has been extensively studied 
Mapping of several syndromic entities in the late 1980s has been rapidly followed by the 
identification of causative genes In approximately half of the syndromic XLMR entities, 
the underlying cause has been elucidated Resolving the genetic causes of non-syndromic 
XLMR has been lagging behind due to the clinical non specificity in combination with 
enormous genetic heterogeneity However, this initial delay is rapidly being catched up and 
at present 21 MRX genes have been resolved, which together explain 24 of the 82 linked 
MRX families with a lodscore>2 
The identification of 21 MRX genes allowed us to explore their functional roles in neuronal 
development and cognitive processes by extending the molecular research to protein studies 
and studies at the cellular level comprising neuronal outgrowth, dendrite formation and 
synapse function Valuable neurobiological information will be provided by animal studies, 
as shown by recent research in thcfmrl knockout ' 1 This suggested a role for FMRP in 
dendritic mRNA transport/translation and synaptic plasticity Such insights in neurobiology 
will form the fundamentals for future therapeutic intervention 
It is especially informative, when different genes are involved in the similar biological 
pathways or neuronal processes Several such common pathways can be recognized 
Among the first MRX genes that were identified, are three genes that encode proteins that 
are involved in RhoGTPase signaling OPHNl, RhoGEF and PAK3 RhoGTPases belong 
to the family of Ras-like GTPases that act in signal transduction pathways and that 
transduce extracellular-derived signals from the cell surface to the actin cytoskeleton of the 
cell and the nucleus They are required for axonal outgrowth and/or establishment and 
stabilization of neural connections 45 Another group of MRX genes encode proteins that 
have a role in the control of gene expression through modulation of the chromatin structure 
MECP2, XNP, RSK2, ZNF41, ZNF8Ì and JARIDIC MECP2 is not only involved in DNA 
methylation, but also histone methylation and is associated with histone H3 methyl 
transferase activity 6 The XNP protein is a PHD Zinc finger domain transcriptional 
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regulator of the SWI/SNF2 family of DNA helicases. XNP is known to interact with HP1 
and EZH2, both of which are heterochromatin-binding proteins 7'8. Like XNP, the two 
closely related ZNF41 and ZNF81 proteins, members of the very large family of KRAB 
domain zinc finger proteins, are found in transcriptional repressor complexes. In contrast, 
the kinase domain protein RSK2 appears to mediate transcriptional activation through its 
activity in the regulation of histone H3 acetylation 9. The role of JARIDIC in histone 
modification has been postulated on basis of the JmjC domain. Proteins containing a JmjC 
domain often have DNA- or chromatin binding domains as well and might therefore 
regulate the integrity of chromatin structure '0. Some of the other MRX genes seem to play 
a role in similar pathways, such as NLGN4 and DLG3 in synaptogenesis I M \ Yet other 
genes and the proteins they encode revealed that the functional spectrum is much broader. 
For instance, ARX is a transcriptional regulator thought to be involved in the differentiation 
of proliferating neuroblasts into GABAergic neurons l4. GDI1 is considered to form 
complexes with Rab proteins which are required for the synaptic vesicle fusion events at 
the synaptic membrane that underlie exocytosis and endocytosis '5'16. IL1RAPL1 may 
regulate calcium-dependent exocytosis and thereby plays a role in synaptic neurotransmitter 
release '7. Moreover, effects on RNA splicing (PQBP1) and RNA translation (FTSJ1) and 
aberrant metabolic processes (SLC6A8, ACSL4) are functional mechanisms also shown to 
be involved in the cause of XLMR '8"21. 
Elucidating the MRX genes and their functions will reveal crucial pathways for normal 
function of the brain and will contribute to broaden the knowledge on pathophysiology of 
X-linked MR. This will form the basis for further neurobiological research in obtaining 
more insight in mental and motor development. In addition, this knowledge will also guide 
the selection of novel candidate genes not only on the X-chromosome but also elsewhere in 
the genome. 
6.2 XLMR: from monogenetic to quantitative trait 
It was already known for over 100 years that more males than females are affected with 
MR. It was generally believed that (monogenic) X-linked factors contributed for a large 
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part to this male excess and early estimations suggested that XLMR accounts for 25% of all 
male MR 22 23. However, recent findings have shown that monogenic XLMR accounts for 
10% of male MR at most, when fragile X syndrome cases are excluded 2425 The mutation 
detection rate in MECP2, ^ÄÄ'and SLC6A8 in sporadic male MR patients estimated in this 
thesis is 0.1 to 0 4%. These three genes are probably among the most frequently mutated 
genes in XLMR Based on the incidence of mutations in the other known MRX genes in 
proven XLMR families it is to be expected that each of them has an even lower mutation 
rate in sporadic MR males. Assuming that the average contribution of each XLMR gene is 
0.1% to the incidence of MR in the male population 2627, it can be estimated that the total 
number of genes responsible for the entire XLMR population (syndromic and non-
syndromic) is about 100. However, for many syndromic and non-syndromic families 
(together about 150) a gene defect still has to be identified Although some of them might 
end up allelic, it is expected that far more than 100 genes will be involved in monogenic 
XLMR entities Therefore, it seems that the average mutation frequency of 0 1% for a given 
XLMR gene is still an overestimate. 
The above prevalence percentages and total gene number counts do not explain the entire 
male excess in the MR population 24. Therefore, it is likely that other (X-chromosomal) 
factors are responsible for the remaining proportion One hypothesis is that X-lmked 
mutations might only lower the IQ range in a subtle way, thus acting as quantitative trait 
loci (QTL)2A2S. In this respect it is noteworthy that the normal distribution of intelligence 
shows not only a male excess at the lower end of the intelligence curve, but also on the 
other end, that of brilliance 28 30. It has been suggested that mental impairment is 
approximate 3 times more frequently associated with genes on the X-chromosome than 
with genes on individual autosomes, even when correcting for the preferential expression of 
X-lmked disorders in hemizygous males 2ίί. This observation of an excess of genes 
responsible for cognitive abilities on the X-chromosome was also recognized for sex-and 
reproduction related genes on the X-chromosme 1I Additionally, it was suggested that the 
X-chromosomal genes involved in the development of cognitive abilities also contribute to 
increased fertility ('brain and testis association'), making males exceptionally prone to 
dysfunction in both the brain and the testis "8 Association studies among cohorts of 
mentally retarded males and brother pair linkage analysis might verify the QTL hypothesis 
in the area of cognition. Other, (non-genetic) factors suggested to account for the 
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male/female ratio are for instance behavioral differences and higher perinatal vulnerability 
in males 32, but is unlikely that these factors constitute a large proportion of the male 
excess 
Besides point mutations or small intragenic deletions, other, yet undetected, X-
chromosomal abnormalities might cause XLMR For example, small X-chromosomal 
duplications might be overlooked because of limitations in the currently used techniques (as 
PCR and karyotyping) Relative novel techniques such as Array CGH, SNP-array mapping 
and MLPA will allow the identification of such small chromosomal alterations and will 
reveal their contributions to the cause of XLMR 
6.3 Diagnosis and genetic counseling 
Historically, XLMR is classified in syndromal and non-syndromal forms Designating an 
XLMR entity as non-syndromic implies that no other clinical features but MR, are 
consistently present among affected individuals Patients initially diagnosed with non-
syndromic MR should therefore be thoroughly re-examined when mutations in MRX(S) 
genes are identified The classical example of the fragile X syndrome illustrates this well 
The family originally described in 1943 as being non-syndromic was restudied in 1981 by 
Richards et al 33, who noted that the affected males showed prognathism, large ears and 
macroorchidism and could therefore be classified as syndromic Another example are the 
more recent findings in patients with OPHN1 mutations The OPHN1 gene was initially 
regarded as a MRX gene, but as pointed out here, because of the cerebellar hypoplasia, 
associated with ventnculomegaly, strabismus and hypogenitalism in patients with an 
OPHN1 mutation, OPHN1 should be regarded as a syndromic XLMR gene Considering a 
metabolic defect consistently present among affected individuals as a syndromic condition, 
SLC6A8 and ACSL4 should be placed exclusively on the syndromic list as well 
In clinical practice, karyotyping and molecular studies of the F MR I gene are commonly 
performed in male patients with MR of unknown cause In larger families, linkage mapping 
may focus mutation screening on one or more of the known XLMR genes present in the 
linkage interval Given that the probability of finding a mutation in a given MRX gene in 
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MR male patients is lower than 0.1% (see 6.2), it is clear that routine screening of MRX 
genes in sporadic patients with non-syndromic mental retardation, is not worthwhile in 
terms of the yield of mutations per gene. Therefore careful clinical examination of males 
with MR is important because this will lead to a preselection for molecular testing in a 
given family. 
In families with OPHNl mutations, distinctive features were consistently present in 
patients. In addition to the frequently reported cerebellar hypoplasia, the ventriculomegaly 
and even hydrocephaly seem prominent features as well. It should be of note that vermis 
hypoplasisa has been observed in other mental retardation syndromes as well (fragile X 
syndrome, Down syndrome)34 and even in males with idiopathic autism 4' , so it should 
not be regarded as a specific sign for the OPHNl phenotype. Therefore, mutation analysis 
seems warranted for familial as well as sporadic MR males with cerebellar vermis 
hypoplasia, associated with ventriculomegaly/hydrocephaly, epilepsy, hypogenitalism and 
strabismus. 
There are two categories of sporadic MR male patients in which MECP2 mutation analysis 
should be considered: males bom with congenital encephalopathy, in particular when there 
is a sister (or close maternal female relative) with Rett syndrome, and males with classic 
Rett syndrome. In the latter, most likely a somatic mosaicism or an XXY karyotype will be 
present. 
In familial cases, MECP2 analysis might be considered in families compatible with X-
linked inheritance, where affected males have MR, spasticity, movement disorder or resting 
tremors and the Xq28 region can not be excluded by linkage analysis. 
Patients with SLC6A8 mutations reported to date, were almost all identified through 
absence of creatine signal upon Η-MRS studies. Features in the younger (sporadic and 
familial) cases indicating creatine deficiency are short stature, low weight gain, hypotonia, 
movement disorder (extrapyramidal, spasticity), seizures, behavior and expressive language 
problems and (in older males), progression of intestinal, neurological and psychiatric 
features could be added. Mutation analysis should be preceded by a urine analysis of the 
creatinexreatinine ratios. Only in patients with abnormal ratios or absence of creatine on H-
MRS, DNA analysis of the SLC6A8 gene should be performed. 
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Figure 8: Schematic illustration of the indications suggested for mutation screening of the genes in the sporadic 
MR male patient as described in this report. For familial cases, see text 
In males with XLAG and Partington syndrome, ARX mutation analysis is indicated in 
familial as well as in sporadic cases. Screening of the gene, especially the 24(bp)dup, is 
indicated also in males with a combination of hypogenitalism, epilepsy (including West 
syndrome and myoclonic epilepsy) and corpus callosum agenesis, especially in familial 
cases and in males with (isolated) dystonic hand movements. In familial cases with MR but 
no other clinical features where Xp22 can not be excluded, testing of the 24(bp)dup might 
be considered as well. 
Males showing a distinct syndromic phenotype comprising MR, short stature with lean 
body habitus, microcephaly, small testes and spasticity, especially when familial should be 
screened for PQBPl mutations. In children the facial characteristics might be absent, and in 
those cases familial X-linked microcephaly may be the only feature that warrants PQBPl 
testing. Since PQBPl mutations were found in a family with a non-syndromic phenotype 
(MRX55), this gene was implicated in both MRX and MRXS. In addition, MECP2, ARX, 
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and JARIDIC appeared mutated in both forms as well, whereas OPHNl and SLC6A8 
should be regarded as syndromic as discussed before. 
In figure 8, a scheme is proposed of clinical features that might lead to such a preselection 
of the relevant genes. 
The identification of the underlying gene defect of XLMR, has greatly enhanced the 
diagnostic possibilities, both pre- and postnatally and thereby improved the genetic 
counseling for the families involved. However, this is to date restricted to a limited number 
of families who almost all have been included in research panels in the past and 
subsequently have been selected for testing of the genes concerned. 
6.4 Autosomal mental retardation 
It has been suggested that 50% of all genes are expressed in the brain 36. Based on this 
figure, well over 500 X-chromosomal genes and thousands of autosomal genes might be 
contributing to normal brain functioning. Based on the available figures, it was estimated 
that 100-130 genes are probably contributing to monogenetic XLMR. Very likely, the 
number of autosomal non-syndromic MR genes will be a multiplex of that. Identifying 
these autosomal MR genes will be even more complex than for X-chromosomal genes, 
because these autosomal conditions will be manifested mainly in isolated cases. So most 
likely hundreds of autosomal genes involved in MR have still to be identified. Many genes 
have been reported in autosomal MR syndromes, including two genes in primary 
microcephaly disorders (ASPM and Microcephalin) 37'1S, but until now, only 1 gene 
(Neurotrypsin) and several loci for non-syndromic autosomal recessive MR have been 
found 39"41. The inheritance pattern in non-syndromic autosomal recessive MR is not always 
recognisable and the mapping and identification of causative genes will largely depend on 
the availability of consanguineous families. Autosomal dominant genes may be identified 
in some cases by using Array CGH, SNP-array analysis and MLPA. Pilot studies have 
shown that interstitial chromosomal duplications or deletions account for another 4-5% of 
unexplained MR, implicating that the total contribution of telomeric and interstitial 
chromosomal abnormalities is in the range of 10-15%)42'43. It is of note that these figures 
largely depend on the patient panels that were specifically selected for and the techniques 
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used in these studies. It has already been shown that these microdeletions harbour novel 
candidate genes for MR 44"47. Breakpoint mapping of translocations involving autosomes in 
mentally retarded patients, has also led to the identification of novel genes. We have shown 
in chapter 5.1 that the gene Eu-HMTasel most likely accounts for the major characteristics 
of the 9q subtelomeric submicroscopic deletion syndrome. Other autosomal genes 
associated with MR identified by breakpoint cloning are CALL, ProSAPI and CNTN4 """^ 
6.5 Future strategies 
For the majority of patients, clinical features will not be specific enough to guide mutation 
analysis for a specific XLMR gene. Therefore, it is obvious that mutation analysis in 
unexplained MR needs to be more robust and cheaper before it is ready to use in clinical 
practice. 
Novel genomic re-sequencing technologies are currently developed, which are much faster 
and may be carried out on an affordable budget of about $1,0005'. In the next decades, high 
throughput analysis technologies might facilitate sequencing of several if not all, MRX 
genes in large patient panels in one experiment. Re-sequencing by single molecule array, is 
such a promising technology 52. 
Although the understanding of molecular mechanisms of XLMR genes and of neural 
function of the proteins they encode are progressing, therapeutic strategies for MR are far 
away. The pathophysiological processes of MR in the human brain are very complex and, 
have most probably started already in early pregnancy. Despite these difficulties, the first 
attempt at treatment with group 1 mGluR antagonists or AMPA receptor enhancers, is 
currently being performed in a cohort of fragile X patients ', (see also 
http://www.fraxa.org/ra Berry-Kravis.aspx.). Future studies might reveal if these 
neuropharmacological approaches are effective as hypothesized, but it might be clear that it 
will take decades for therapeutic interventions to come. In addition to pharmaceutical 
intervention, one should not forget the positive effects that can be obtained by conventional 
"treatment", i.e. offering MR individuals a stimulating and activating environment. 
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Progressing molecular and clinical studies are crucial to further unravel the pathways 
involved in MR and will set the foundations of future therapeutic intervention. This is not 
only a challenging but also an obligatory task we owe the patients and families involved. 
More information on X-linked mental retardation can be found on several websites: 
www.euromrx.com, www.ggc.org/xlmr.htm, http://xlmr.interfree.it/home.htm 
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This thesis describes the results of clinical and molecular studies in patients with X-linked 
mental retardation (XLMR). Starting point of this research was firstly, to identify novel 
genes responsible for XLMR and secondly, to perform thorough clinical studies in patients 
in whom the underlying genetic cause was resolved. Therefore, the general goal was to 
increase the possibilities for DNA diagnostics and genetic counseling in patients and 
families with so far unexplained mental retardation (MR). 
Identification of non-syndromic XLMR genes 
Historically XLMR is divided in syndromic XLMR and non-syndromic XLMR. In patients 
with the latter form, MR is the only clinical feature consistently present. Therefore, 
identification of genes involved in non-syndromic MR is more difficult than in syndromic 
XLMR, as families can not be pooled for narrowing down candidate regions harbouring 
causal genetic defects. Despite this difficulty, identification of genes responsible for non-
syndromic XLMR has increased considerably in the recent years, resulting in 21 genes to 
date. Conventional strategies for gene identification are positional cloning and positional 
candidate gene analysis. Both are still useful techniques in the search for novel candidate 
genes for XLMR. One example of each approach is given in chapter 2. 
By linkage analysis in a family with seven affected males, the causative genetic defect was 
mapped to a interval on Xp22.3-Xp21.3 (chapter 2.1). Subsequent candidate gene analysis 
of ILJRAPLl, RSK2 and ARX, revealed a mutation in the latter gene. A recurrent 24-bp 
duplication in exon 2 was shown to segregate with the phenotype in this family. In addition, 
by cloning of the X-chromosomal breakpoint of a de novo translocation 
t(X;9)(pl 1.23;q34.3) in a mentally retarded female, the ZNF8J gene was identified (chapter 
2.2). Subsequent mutation analysis of this gene in more than 300 families and patients with 
non-syndromic X-linked mental retardation, revealed a sequence change p.S179N in family 
MRX45, fully segregating with the phenotype. ZNF81 is highly homologous to ZNF4I, 
another zinc finger gene associated with non-syndromic X-linked mental retardation. 
Together, these data suggest that ZNF81 represents a novel MRX gene which is causally 
involved in a minority of patients with non-specific X-linked mental retardation. 
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Frequency of MRX genes in MR population 
Since it appeared that some genes were mutated relatively frequently in families with non-
syndromic XLMR, the question was raised whether routine testing of these genes would be 
practical in patients with MR of unknown cause. 
In chapter 3, mutation screening of the MECP2 gene in four different patient panels is 
reported; 475 mentally retarded males, negative for molecular analysis of the FMRPl gene 
(fraX negative males, chapter 3.1), 92 mentally retarded females, negative for molecular 
analysis of the FMRPl gene (fraX negative females) and 63 mentally retarded males and 
females, negative for molecular analysis of Angelman syndrome (Angelman negative males 
and females, chapter 3.2). Mutations were found 1 of the 475 fraX negative males, in 1 of 
the 92 fraX negative females and in 2 of the 63 Angelman negative males and females. 
Because of some phenotypic overlap of the male patient identified in the fraX negative 
males and because the chromosomal region 15ql l-ql3 might be influenced by the MECP2 
protein, we considered to search for mutations in Prader-Willi negative patients. Therefore, 
additionally 98 mentally retarded males and females negative for molecular testing of the 
Prader-Willi syndrome were tested, but no mutations were found (chapter 3.2). Therefore, 
only in patients with a clinical diagnosis of Angelman syndrome, but without molecular 
abnormalities on 15ql l-ql3, routine screening of the MECP2 gene is worthwhile. 
Genotype-phenotype studies in XLMR 
It has been observed that several genes identified in patients with an XLMR syndrome also 
give rise to a non-syndromic phenotype and vice-versa: OPHN1, MECP2, SLC6A8, RSK2, 
FGD1, XNP, ARX, PQBP1 and JARIDIC. A subclassification of the clinical features into 
syndromic/non-syndromic MR should be the first step in the differential diagnoses of MR 
patients and will indicate if a candidate gene screen should be undertaken. Therefore, 
careful clinical examination and genotype-phenotype studies are important tools. We 
focused on six of these genes and reviewed the clinical and molecular characteristics known 
so far. OPHN1 should be regarded as a syndromic XLMR gene and based on the metabolic 
abnormalities, SLC6A8 and ACSL4 as well. 
In chapter 4, the clinical features and genotype-phenotype correlations of three genes have 
been studied in more detail. A male patient, with a MECP2 mutation was evaluated. He 
showed moderate MR, truncal obesity, gynaecomastia, hypotonia, breathing and mood 
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disturbances (chapter 4 1) Re-examination of three families with PQBP1 mutations was 
performed after the initial report on involvement of this gene in XLMR (chapter 4 2) The 
characteristics were compared with two other families known with mutations in this gene 
Renpennmg syndrome and Sutherland-Haan syndrome In summary, the most common 
features were mental retardation (70% severe MR), microcephaly (93%), short stature and 
lean habitus (61%), post-adolescent facial characteristics, small testes (32%), spastic 
diplegia (20%) and midline defects Two families with mutations in the SLC6A8 gene were 
clinically evaluated (chapter 4 3) In the younger patients, neuro-muscular problems were 
prominent, but based on the features observed in the older patients in this study and in two 
older male patients of another family, it seemed that the clinical phenotype was progressing 
with age and comprised intestinal problems, severe myopathy and mood disturbances as 
well 
Autosomal Mental Retardation 
Recent findings reviewed in this thesis show that the prevalence of monogenic XLMR (ΙΟ­
Ι 2%) can not explain the male excess of approximate 30% in the mentally retarded 
population Other causes as non-genetic factors, polymorphisms or 'subtle' X-linked 
changes (quantitative trait loci, QTL) are proposed to account for part of the remaining Sib 
pair analysis and association studies have to be carried out to verify this hypothesis It was 
estimated that 100-130 genes are probably contributing to monogenetic XLMR Very 
likely, the number of autosomal non-syndromic MR genes will be a multiplex of that In 
chapter 5, the association of an autosomal gene in the cause of MR is reported By further 
studying the breakpoint on chromosome 9q34 3 of the translocation described in chapter 
2 2, and the clinical resemblance with patients with subtelomenc submicroscopic 9q 
deletions, it is hypothesized that the gene Eu-HMTasel is responsible for the major 
characteristics of the 9q deletion syndrome Moreover, expression studies of the gene in the 
mouse brain, revealed that the gene was widely expressed during embryogenesis and was 
restricted to regions known to be crucial in learning and memory development in the adult 
brain 
Some of the currently known genes involved in (non-syndromic) XLMR have been shown 
to act in similar cellular pathways such as the interaction with RhoGTPases (OPHN1, 
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RhoGEF and PAK3) and by histone modulation (RSK2, MECP2, XNP, ZNF4I and ZNF8I). 
Elucidating the functions of the known genes, will unravel the pathways essential for 
normal brain function and will also help to select novel candidate genes for MR. It is clear 
that, based on the knowledge to date, routine screening of MRX genes in sporadic patients 
with non-syndromic mental retardation, is not feasible in terms of the yield of mutations per 
gene. In the next decades, high throughput analysis technologies might facilitate sequencing 
of several if not all, MRX genes in large patient panels in one experiment. The 
identification of the molecular pathways will set the foundations for further neurobiological 
research as currently being performed in mouse models and by in vitro studies on the 
cellular level. 
The pathophysiological processes of MR in the human brain are very complex and, have 
most probably started already in early pregnancy making therapeutic intervention a difficult 
task. Therefore, continuing molecular, cellular, animal and clinical studies is crucial to 
further unravel the pathways involved in MR and will set the foundations of future 
therapeutic intervention, which is not only a challenging but also an obligatory task we owe 




Dit proefschrift beschrijft de resultaten van klinisch en moleculair onderzoek bij patiënten 
met X-chromosomaal gebonden verstandelijke handicap (XLMR) Het uitgangspunt bij dit 
onderzoek was om middels daarvoor geschikte patiënten en families nieuwe genen 
verantwoordelijk voor XLMR te identificeren en om naar patiënten en families, waarin de 
genetische oorzaak opgehelderd werd, terug te gaan voor nauwgezet klinisch onderzoek 
Dit met als uiteindelijke doel, het verbeteren van diagnostiek en counseling in families en 
patiënten waarbij tot voor kort geen oorzaak voor hun mentale retardatie (MR) bekend was 
De identificatie van genen verantwoordelijk voor niet-syndromale XLMR 
Traditioneel worden patiënten met XLMR onderverdeeld in syndromale XLMR (MRXS) 
en niet-syndromale XLMR (MRX), waarbij in de laatste groep de MR het enige klinische 
kenmerk is dat consistent aanwezig is bij de patiënten De identificatie van 
verantwoordelijke genen op het X-chromosoom is moeilijker in deze tweede groep, omdat 
de families niet gegroepeerd kunnen worden voor koppelmgsonderzoek, zoals dat wel kan 
in families met hetzelfde syndromale fenotype Ondanks deze moeilijkheid, zijn er reeds 21 
genen geïdentificeerd die verantwoordelijk zijn voor MRX, waarmee het oorzakelijke 
gendefect in 30% van de families die koppelen op het X-chromosoom (lodscore>2) is 
aangetoond Conventionele methoden voor het opsporen van kandidaat-genen zijn 
positioneel kloneren en positioneel kandidaat gen analyse In hoofdstuk 2, is van beide 
methoden een voorbeeld gegeven 
Met behulp van koppelmgsonderzoek werd in een familie met zeven mannen met MR, de 
positie van het oorzakelijke gendefect gelokaliseerd in het gebied Xp22 3-Xp21 3 
(hoofdstuk 2 1 ) Het daarop volgende mutatie onderzoek van de bekende kandidaat genen 
gelegen in dit interval IL1RAPL1, RSK2 en ARX, resulteerde in het vinden van een mutatie, 
een frequent beschreven 24-bp duplicatie in exon 2 van het ARX gen bleek 
verantwoordelijk voor de MR in deze familie 
Bij het in kaart brengen van het breukpunt op het X-chromosoom van een de novo 
translocatie t(X 9)(pl 1 23, q34 3) in een mentaal geretardeerde vrouwelijke patient, werd 
het ZNF81 gen geïdentificeerd (hoofdstuk 2 2) Vervolgens werd mutatieanalyse van dit 
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gen in een cohort van ruim 300 families en patiënten uitgevoerd. Hierbij werd een mutatie 
(p.S179N) gevonden in familie MRX45, die volledig segregeerde met het (niet-
syndromale) fenotype. Deze bevinding, samen met het feit dat ZNF8I homoloog is aan een 
eveneens met XLMR geassocieerd gen, ZNF41, suggereert dat het ZNF81 gen een nieuw 
MRX gen is dat in een minderheid van de patiënten met XLMR, verantwoordelijk is voor 
de mentale retardatie. 
Frequentie van MRX mutaties in de mentale retardatie populatie 
Omdat bleek dat sommige genen redelijk frequent gemuteerd waren in families met niet-
syndromale XLMR, was het de vraag of het standaard testen van mutaties in deze genen in 
mentaal geretardeerde (sporadische) patiënten waarbij de oorzaak van de retardatie 
onbekend was, zinvol zou zijn. Daarom werden vier verschillende groepen op mutaties in 
het MECP2 gen onderzocht (hoofdstuk 3). Mutaties werden gevonden in 1 van de 475 
mannelijke MR patiënten, zonder DNA afwijking passend bij het fragiele X syndroom 
(fraX negatief), in 1 van de 92 fraX negatieve vrouwelijke MR patiënten en in 2 van de 63 
MR patiënten van beide geslacht zonder DNA afwijkingen passend bij het Angelman 
syndroom. Omdat er overlap was in het fenotype van de patiënt gevonden in het cohort van 
de fraX negatieve mannen met het Prader-Willi syndroom en omdat de chromosomale regio 
15ql l-ql3 mogelijk een target is voor MECP2, overwogen wij om een additionele groep 
van 98 Prader-Willi negatieve patiënten te screenen op mutaties. In deze groep werden er 
echter geen mutaties gevonden (hoofdstuk 3.2). Samenvattend kan geconcludeerd worden 
dat het alleen bij patiënten met een klinische diagnose Angelman syndroom, maar zonder 
moleculaire afwijkingen van 15qll-ql3, zinvol is om te zoeken naar mutaties in het 
MECP2 gen. 
Genotype-fenotype onderzoek in XLMR 
In hoofdstuk 4 zijn de klinische kenmerken en genotype-phenotype relaties van drie genen 
nader bestudeerd. De patiënt bij wie een MECP2 mutatie was gevonden zoals uiteengezet is 
in hoofdstuk 3.1, werd onderzocht. Bij hem was sprake van een matige verstandelijke 
handicap, overgewicht met name in de romp, vetophoping in borstweefsel, hypotonie, 
ademhalingsproblemen en stemmingswisselingen (hoofdstuk 4.1). Prentaal onderzoek kon 
worden verricht bij de moeder van deze patiënt, die nu de oorzaak bekend was, een tweede 
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zwangerschap aandurfde Klinisch onderzoek van zeven mentaal geretardeerde patiënten uit 
drie verschillende families met een PQBP1 mutatie werd verricht (hoofdstuk 4 2) De 
kenmerken werden vergeleken met de fenotypen van twee andere 'klassieke' XLMR 
families met een recent gevonden PQBP1 verandering Renpenning syndroom en 
Sutherland-Haan syndroom De meest voorkomende verschijnselen bleken MR (70% 
ernstig), microcefalie (93%), kleine testes (32%), spasticiteit (20%) en defecten in de 
middenlijn Prenatale diagnostiek kon worden verricht in een van de families, nu de 
verantwoordelijke mutatie in het PQBP1 gen bekend was Tenslotte werden twee families 
met mutaties in het SLC6A8 gen klinisch onderzocht (hoofdstuk 4 3) Bij patiënten in de 
kinderleeftijd zijn hypotonie, klein postuur en spraak-taal problemen frequent voorkomende 
problemen Echter, gebaseerd op de bevindingen in oudere patiënten in de huidige studie en 
in twee oudere mannen beschreven in de literatuur, lijkt het klinisch beeld progressief te 
zijn en omvat wellicht ook darmproblemen, spierzwakte en stemmingsstoornissen op latere 
leeftijd 
Klinisch onderzoek van patiënten is belangrijk omdat dit de eerste stap is in het 
diagnostisch proces en bepaalt of en voor welk XLMR gen DNA diagnostiek nodig is 
Bovendien verbetert dit de kennis ten behoeve van counseling van zowel de betreffende 
families als van andere families 
Autosomaal recessieve Mentale Retardatie 
Recente artikelen rapporteren dat het voorkomen van monogene XLMR ongeveer 10-12% 
is en dat dit percentage niet het man/vrouw overschot van 30% in de totale MR populatie 
kan verklaren Andere oorzaken zoals met-genetische factoren, polymorfismen of 'subtiele' 
X-gebonden veranderingen (quantitative trait loci, QTL) zijn verondersteld 
verantwoordelijk te zijn voor het resterende deel Sib paar analyse en associatie studies 
zouden moeten uitwijzen of deze laatste hypothese klopt Het totaal aantal genen dat 
verantwoordelijk is voor XLMR bedraagt waarschijnlijk 100-130 en het aantal 
verantwoordelijk voor autosomaal recessieve MR wellicht een veelvoud hiervan 
In hoofdstuk 5 is de associatie van een autosomaal gen met MR beschreven Nadat in de 
literatuur enkele malen werd gerapporteerd dat patiënten met een subtelomere 9q deletie 
een klinisch herkenbaar syndroom hebben (9q- syndroom), bleek de index patient van de 
translokatie beschreven in hoofdstuk 2 2, opvallende gelijkenis met deze patiënten te 
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vertonen. Nadere expressie studies in de muis van het gen verstoord door het breukpunt in 
9q34.3 (Eu-HMTasel), lieten zien dat het zeer aannemelijk is dat dit gen verantwoordelijk 
is voor de meeste kenmerken van het 9q- syndroom. 
Van enkele genen die betrokken zijn bij MRX(S) is gebleken dat ze overeenkomstige 
functies hebben en betrokken zijn bij dezelfde mechanismen zoals de interactie met 
RhoGTPases (OPHNI, RhoGEF and PAK3) en histon modificatie (RSK2, MECP2, XNP, 
ZNF41 and ZNF81). Het verder ontrafelen van de functies van de bekende genen, is van 
belang zijn voor het herkennen van paden die een rol spelen bij normale 
hersenontwikkeling en functie en zal ook helpen in de selectie van nieuwe kandidaat genen 
voor XLMR. Ook zal dit de basis zijn voor verder neurobiologisch onderzoek zoals 
momenteel wordt gedaan in muismodellen en in vitro studies. 
Het is duidelijk dat gebaseerd op de huidige kennis en technieken, het routine matig testen 
van MRX genen op mutaties in sporadische patiënten met niet-syndromale MR niet zinvol 
is. Over enige tijd zullen snelle, efficiëntere technieken het waarschijnlijk wel mogelijk 
maken om vele, zo niet alle, MRX genen te onderzoeken in grote aantallen patiënten. De 
pathofysiologische processen van MR in hersenen zijn zeer complex en ontwikkelen zich al 
zeer vroeg in het embryonale leven. Dit maakt therapeutische interventie zeer lastig. Het 
continueren van moleculair, cellulair, dier-experimenteel en klinisch onderzoek, is daarom 
essentieel voor het verder ontcijferen van de complexiteit van MR en zal ook nodig zijn om 
in de toekomst wel therapie te kunnen bieden. Dit is niet alleen een grote uitdaging, maar 
ook een verplichting aan de patiënten en de families die hierbij betrokken zijn. 
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Graag wil ik mij aan het eind van dit proefschrift richten op de personen die allemaal een 
klein of een groot steentje hebben bijgedragen aan het tot stand komen hiervan. 
In het bijzonder alle patiënten en hun familieleden die ik, over het algemeen, thuis bezocht 
en die mij altijd weer deden beseffen dat er bij ieder DNA monster op het laboratorium, een 
eigen, vaak indrukwekkend verhaal hoort. Grote bewondering heb ik voor de manier 
waarop deze families soms al generaties lang, omgaan met de verstandelijke handicaps bij 
hun kinderen/broers/zussen/ooms/tantes. 
Ben, ik ben er trots op dat jij niet alleen mijn opleider bent, maar sinds vandaag ook zwart 
op wit in mijn proefschrift, als mijn promotor staat vermeld. Jij zat niet 'boven op' mijn 
onderzoek, dat heb ik zeer gewaardeerd. Jij liet mij mijn gang gaan, maar was er als ik je 
raad, hulp of advies nodig had. Rustig en betrouwbaar. Jij kende de weg in de XLMR 
wereld en daar heb ik volop van kunnen leren en van kunnen profiteren! 
Hans, jij was er om mij op het moleculaire vlak te sturen. Jij maakte altijd tijd als ik er om 
vroeg, zorgde gelijk voor opheldering van zaken waar ik vragen over had en keek kritisch 
naar mijn artikelen. Als ik bij jou vandaan kwam had ik weer structuur in mijn gedachten 
en zag alles er veel simpeler en overzichtelijker uit dan daarvoor! 
Bert, jij was onophoudelijk enthousiast naar de bevindingen en resultaten. Je dacht aktief 
mee en keek mijn artikelen ook snel en vooral zeer analytisch na. Met het 9q werk kwam ik 
toch nog helemaal in jouw straatje terecht en door jou is tabellen maken bijna mijn hobby 
geworden! 
Han, hoewel niet direct betrokken bij mijn onderzoek, liet je op de juiste momenten van je 
horen. Bewonderenswaardig hoe jij ondanks de enorme groei van de afdeling, kritisch en 
enthousiast blijft meedenken met al het werk wat op de afdeling wordt verzet. 
Helger, jij hielp mij op weg in een voor mij zware periode waarin ik tevens moest beginnen 
met het daadwerkelijke AGIKO traject. Jij begeleidde aanvankelijk het project rondom de 
breukpuntidentificatie en initieerde de benodigde experimenten. Later nam jij meer afstand 
en kreeg ik zelf alles steeds beter in de vingers. Maar zat ik weer eens omhoog om het een 
of ander, jij wist altijd raad. Bedankt voor al jouw hulp! 
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Dorien, jij hebt al mooie onderzoeksresultaten wat ongetwijfeld tot een goede promotie zal 
leiden Ik hoop de resterende tijd nog vaak met jou te discussieren over XLMR én andere 
zaken Ik mis het 'even koffie drinken9' nu al .. 
Arjan, pas sinds enige tijd onder het XLMR-dak, maar je stempel al aardig aan het achter 
laten. Soms gingen jouw gedachten mij iets te snel, maar geduldig legde je het dan allemaal 
nog wel weer een keertje uit. Voor al jouw ideeën is het lab te klein, maar er zullen vast ook 
wel mooie resultaten uit voortvloeien' 
Martijn, ookjij hebt je naam gevestigd binnen het lab Het was even wennen, maar al gauw 
bleek die 'stille jongen' een gehele andere kant te hebben. Jouw humor werkte zeer 
aanstekelijk. Ik bewonder jouw tomeloze inzet en enthousiasme in de zoektocht naar DE 
mutatie en hoop dat er nog vele successen zullen volgen! 
Astrid, JIJ hebt mij enige tijd geleden, de moleculaire kneepjes (opnieuw) moeten 
bijbrengen Je nam de tijd maar was zeer structureel en in jou handen leek soms alles te 
lukken 
Enk en Willy, vanuit de DNA diagnostiek zijn jullie zeer betrokken geweest bij mijn werk, 
ik heb onze samenwerking als heel prettig ervaren en hoop dat dit nog jaren zo mag blijven' 
Dear colleagues of the European-XLMR consortium, many thanks for the collaboration 
within the consortium. I hope that we continue this way, that we can be of even more help 
for the patients and families and may have many more successes in the future' 
Sylvia (mijn bondgenoot-moeder-30+<'r), Jeroen, Martijn J, ook mede dankzij jullie heb ik 
het erg plezierig gevonden op het lab te zijn, al was het misschien soms wel eens een beetje 
té gezellig . 
Alle andere (ex-)collega's van moleculaire genetica. Het is ondoenlijk om iedereen te 
noemen, maar heel erg bedankt voor de prettige samenwerking Als ik mij op het lab of in 
de celkweek vertoonde, stond er altijd wel iemand klaar om mij te vertellen waar iets stond, 
waar ik wat waarin weg moest gooien, of hoe bepaalde apparaten en computerprogramma's 
nu weer werkten Dank! ! 
Ernie, Marleen, Manken, met jullie heb ik al vele jaren menig kamer en hef-en-leed 
gedeeld. Bedankt voor al jullie begrip, uitlaat kwartiertjes, handige tips en vooral ook 
plezier Ik hoop dat jullie nog heel lang mijn collega's zijn! 
Alle andere lieve mensen van de klinische genetica, jullie maken het hier (bijna.. ) mijn 
tweede thuis , ik hoop nog heel, heel lang bij jullie te blijven" 
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Monique, Karlijn en Saskia, intussen wonen wij her en der in het land en hebben onze eigen 
carrières en gezinnen. De pot-v-4 afspraakjes zijn daarom wat minder frequent, maar zeker 
niet minder waardevol. Bedankt voor al die jaren vriendschap! 
Jan Kees, Els, oma Mary, bedankt voor het altijd klaar staan en voor de interesses in ons en 
in de kinderen! 
Lolke en Ylse, bedankt voor de steun-op-afstand. Sinds het e-mail tijdperk is Zwitserland 
vaak dichterbij dan Friesland! 
Leave heit en mem, jullie brachten mij bij om 'troch te selten' en nooit 'de kop hingje te 
litten'. Jullie stonden letterlijk aan de wieg van mijn verdere ontwikkeling en 
onvoorwaardelijk achter mijn keuzes, al zullen jullie vast wel eens je bedenkingen hebben 
gehad. Bedankt voor het altijd klaar staan!! 
Mark Edo, Silke en Mette, mijn âller-âller-liefsten. Ik realiseer mij iedere dag weer, hoe 
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behorend bij het proefschrift 
Genotypes and Phenotypes 
in X-linked Mental Retardation: 
from families to genes and back 
Met de huidige technieken is het niet geïndiceerd routinematig mutatie onderzoek van 
MRX(S) genen te doen bij sporadische mannelijke patiënten met niet-syndromale mentale 
retardatie. 
dit proefschrift 
ZNF81 is hoogstens verantwoordelijk voor een zeer klein deel van niet-syndromale XLMR. 
dit proefschrift 
SLC6A8 en ACSL4 horen uitsluitend thuis in het MRXS-genen lijstje. PQBP1 zeer 
waarschijnlijk ook. 
dit proefschrift 
Eu-HMTasel is verantwoordelijk voor de hoofdkenmerken van het 9q- syndroom. 
dit proefschrift 
Gezien de toename in mogelijkheden van genetische testen en vraag naar genetisch 
onderzoek, zouden perifere top-klinische ziekenhuizen meer moeten investeren in de 
Klinische Genetica. 
Finger length ratio (2D:4D) correlates with physical aggression in men but not in women. 
Allison Bailey & Peter Hurd, Biological Psychology 86 (2005) 215-222. 
Het meisje van de 'Thea-studeert-techniek' generatie werd op haar studie mogelijkheden en 
arbeidstoekomst gewezen. Er is destijds vergeten erbij te vermelden dat 'Thea-wordt-moeder' 
ook ergens ingepast moet worden. 
Vluchtige bestanddelen uit het tijmkruid versterken de hoestwerende werking van de in water 
oplosbare bestanddelen. 
Chemisch en pharmacologisch onderzoek naar de waarde van tijmpreparaten. JC de 
Keuning, Rotterdam, 1951. 
De afstand 'Radboud-Waalsprong', wordt niet sneller afgelegd met de Snelbinder. 
Eigen waarneming 
Barak: het is nog niet echt comfortabel wonen, maar het is een begin. 
Loesje. 
Nijmegen, 29 juni 2005 
Tjitske Kleefstra 



